Regulation of Connective Tissue Growth Factor (CTGF) in
hypertension-induced end organ damage
Piet Finckenberg
Institute of Biomedicine
Pharmacology
University of Helsinki
Academic Dissertation
To be presented, with the permission of the Faculty of Medicine, University of Helsinki, for public
examination in the auditorium “Richard Faltin” of the Fourth Department of Surgery, Helsinki
University Central Hospital, Helsinki, on 12 December, 2003, at 12 noon.
Supervisors
Docent Eero Mervaala Professor Leena Lindgren
Institute of Biomedicine, Pharmacology Department of Anaesthesia
University of Helsinki Tampere University Hospital
Helsinki, Finland Tampere, Finland
Reviewers
Professor (emer.) Eero Saksela Docent Ilkka Pörsti
Department of Pathology Department of Internal Medicine
University of Helsinki Tampere University Hospital
Helsinki, Finland Tampere, Finland
Opponent
Professor Gerald F. DiBona
Department of Internal Medicine
University of Iowa College of Medicine
and Veterans Administration Medical Center
Iowa City, Iowa, USA
Cover: Myocardial Expression of CTGF mRNA in dTGR rat
ISBN 952-91-6656-7 (paperback) ISBN 952-10-1498-9 (PDF, http://ethesis.helsinki.fi)
Helsinki, 2003, Yliopistopaino
TABLE OF CONTENTS
LIST OF ORIGINAL PUBLICATIONS 7
ABBREVIATIONS 8
ABSTRACT 10
1 INTRODUCTION 12
2 REVIEW OF THE LITERATURE 14
2.1 CONNECTIVE TISSUE GROWTH FACTOR (CTGF) 14
2.1.1 Structure and physiological functions 14
2.1.2 Regulation of CTGF expression 17
2.1.3 Role of CTGF in pathological states 18
2.1.4 Therapeutic approaches to prevent CTGF overexpression 20
2.2 HYPERTENSION-INDUCED END ORGAN DAMAGE 20
2.2.1 Lesions of the heart, vasculature and kidney 20
2.2.1.1 Sympathetic nervous system in the pathogenesis of hypertension-induced
end organ damage 21
2.2.1.2 Involvement of the mechanical factors 22
2.2.1.3 Involvement of the hormonal factors and inflammation 23
2.2.1.3.1 Angiotensin II 26
2.3 ANIMAL MODELS USED IN THE PRESENT STUDY 30
2.3.1 Spontaneously hypertensive rat (SHR) (Study I) 30
2.3.2 Double transgenic rat harboring human renin and angiotensinogen genes (dTGR)
(Study II, III, IV) 30
2.4 COMPOUNDS USED IN THE PRESENT STUDY 31
2.4.1 Enalapril (study I) 31
2.4.2 Valsartan (study I, II) 31
2.4.3 -Lipoic acid (study III) 32
2.4.4 Cyclosporine A (CsA) (study I, II) 32
2.4.5 Tacrolimus (FK 506) (study IV) 33
2.4.6 Everolimus (SDZ RAD) (study II) 33
2.4.7 Magnesium (study IV) 34
3 AIMS OF THE STUDY 35
4 MATERIALS AND METHODS 36
4.1 EXPERIMENTAL ANIMALS 36
4.2 EXPERIMENTAL DIETS AND DRUG TREATMENTS 36
4.3 MEASUREMENT OF BLOOD PRESSURE 37
4.4 METABOLIC STUDIES 37
4.5 COLLECTION OF THE SAMPLES 37
4.6 HISTOLOGY 37
4.6.1 Sample preparation 37
4.6.2 Tissue morphology and scoring of the samples 38
4.7 DETECTION OF mRNA FOR CTGF, COLLAGENS I AND III, AND TGF ββββ1 38
4.7.1 In situ hybridization 38
4.7.2 Northern blot 39
4.7.3 Reverse transcriptase-polymerase chain reaction (RT-PCR) assay for CTGF mRNA 40
4.8 IMMUNOHISTOCHEMISTRY 40
4.9 BIOCHEMICAL DETERMINATIONS 41
4.10 STATISTICAL ANALYSIS 41
4.11 ETHICS OF THE STUDY 41
5 RESULTS 42
5.1 BRIEF SUMMARY OF THE MAIN RESULTS 42
5.2 BLOOD PRESSURE AND CARDIAC HYPERTROPHY 43
5.3 URINARY PROTEIN EXCRETION 43
5.4 HISTOPATHOLOGY 44
5.4.1 Myocardial lesions 44
5.4.2 Renal lesions 45
5.5 EXPRESSION OF CTGF 46
5.5.1 Myocardial expression of CTGF 46
5.5.2 Renal expression of CTGF 47
5.5.3 Time- and blood pressure-dependent expression of CTGF 47
6 DISCUSSION 49
6.1 METHODOLOGICAL ASPECTS 49
6.1.1 Increased RAS activity in SHR and dTGR 49
6.1.2 Blood pressure measurements 50
6.2 EFFECT OF BLOOD PRESSURE ON CTGF EXPRESSION 51
6.3 EFFECT OF ANG II AND INFLAMMATORY RESPONSE
ON CTGF EXPRESSION 52
6.4 POSSIBLE CLINICAL IMPLICATIONS 55
7 SUMMARY AND CONCLUSIONS 56
ACKNOWLEDGEMENTS 57
REFERENCES 60
ORIGINAL PUBLICATIONS 75
7
LIST OF ORIGINAL PUBLICATIONS
This thesis is based on the following original publications, referred to in the text by the Roman
numerals I-IV, and some unpublished data:
I Finckenberg P, Lassila M, Inkinen K, Pere AK, Krogerus L, Lindgren L, Mervaala E, Vapaatalo H, Nurminen ML, Ahonen J. Cyclosporine induces myocardial connective tissue growth factor in spontaneously hypertensive rats on high-sodium diet. Transplantation 2001, 71:951-958
II Finckenberg P, Inkinen K, Ahonen J, Merasto S, Louhelainen M, Vapaatalo H, Müller D, Ganten D, Luft F, Mervaala E. Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways. Am J Pathol 2003, 163:355-366
III Mervaala E, Finckenberg P, Lapatto R, Muller DN, Park JK, Dechend R, Ganten D, Vapaatalo H, Luft FC. Lipoic acid supplementation prevents angiotensin II-induced renal injury.
Kidney Int 2003, 64:501-508 (P. F. sharing the first authorship with E. M.)
IV Finckenberg P, Merasto S, Lindgren L, Vapaatalo H, Müller D, Luft F, Mervaala E. Magnesium supplementation prevents angiotensin II-induced myocardial damage and CTGF overexpression.
(Submitted)
The original publications are reprinted with the permission of the copyright holders.
8
ABBREVIATIONS
ACE angiotensin converting enzyme
Ang angiotensin
ANOVA analysis of variance
AP-1 activator protein-1
AT1 angiotensin II type 1 receptor
AT2 angiotensin II type 2 receptor
ATP adenosine triphosphate
BCE-1 basal control element-1
cAMP cyclic adenosine monophosphate
CD4 co-receptor expressed on helper T cells
CD8 co-receptor expressed on cytotoxic T cells
CHF congestive heart failure
Col I collagen type I
Col III collagen type III
CsA cyclosporine A
CTGF connective tissue growth factor
DCM dilated cardiomyopathy
DNA deoxyribonucleic acid
dTGR double transgenic rat harboring human renin and angiotensinogen genes
ECM extracellular matrix
ED1 antibody recognizing rat monocytes and macrophages
ED2 antibody recognizing rat monocytes
EMSA electrophoretic mobility shift assay
FGF fibroblast growth factor
FKBP FK506 binding protein
GAPDH glyceraldehyde-3-phosphate dehydrogenase
G-CSF granulocyte colony-stimulating factor
GM-CSF granulocyte-macrophage colony-stimulating factor
hAOGEN human angiotensinogen
HPLC high-pressure liquid chromatography
hREN human renin
9
ICAM-1 intercellular adhesion molecule-1
IFN interferon
IGF insulin-like growth factor
IL interleukin
LVH left ventricular hypertrophy
MAP(K) mitogen-activated protein (kinase)
mTOR mammalian target of rapamycin
mRNA messenger ribonucleic acid
NADPH nicotinamide adenine dinucleotide phosphate
NFAT nuclear factor of activated T cells
NF-κB nuclear factor kappa B
PCNA proliferating cell nuclear antigen
PDGF platelet-derived growth factor
PKC protein kinase C
PRA plasma renin activity
RAS renin-angiotensin system
RDA recommended daily allowance
RT-PCR reverse transcriptase-polymerase chain reaction
ROS reactive oxygen species
SBP systolic blood pressure
SD Sprague-Dawley rat
SHR spontaneously hypertensive rat
TβRE transforming growth factor beta-response element
TGFβ transforming growth factor beta
TNF tumor necrosis factor alpha
TOR target of rapamycin
TSP-1 thrombospondin-1
VCAM-1 vascular cell adhesion molecule-1
VSMC vascular smooth muscle cell
WKY Wistar Kyoto rat
10
ABSTRACT
Hypertension is a major risk factor for the development of cardiovascular complications such as
atherosclerosis, myocardial infarction, stroke and renal failure. In common to these adverse events
is the accumulation of connective tissue in the involved structures. The exact mechanisms
contributing to the regulation of connective tissue homeostasis in hypertension are still obscure.
Recently an important regulator of the connective tissue synthesis was found, and named
“connective tissue growth factor” (CTGF). During the recent years accumulating evidence has
connected CTGF overexpression with various inflammatory and fibrotic diseases. The present
series of studies were conducted to investigate the role of the CTGF in hypertension-induced end
organ damage. Special attention was focused on angiotensin II (Ang II), an effector molecule of the
renin-angiotensin system (RAS), as a regulator of the CTGF gene expression.
Cyclosporine (CsA)-treated spontaneously hypertensive rats (SHR) on high sodium diet (7-9 weeks
old) and double transgenic rats harboring human renin and angiotensinogen genes (dTGR) (3-4
weeks old) were used as hypertensive animal models with increased RAS activity. The roles of the
blood pressure and Ang II as regulators of the CTGF gene expression were studied. To further
elucidate the regulatory mechanisms of the CTGF gene, intervention studies with antihypertensive
drugs (ACE inhibitor enalapril, AT1 receptor antagonist valsartan), immunosuppressives (CsA,
tacrolimus, everolimus), antioxidant (-lipoic acid) as well as with magnesium were conducted.
Blood pressure was recorded, the relative organ weights measured, mediators of inflammation were
detected with immunohistochemistry and electrophoretic mobility shift assay. Tissue morphology
was examined and the expression of myocardial and renal CTGF mRNA was determined with in
situ hybridization, Northern blot and RT-PCR.
Arterial hypertension induced the expression of the myocardial CTGF mRNA in CsA-treated SHRs.
The expression of the CTGF gene correlated closely with blood pressure, and was prevented with
concomitant antihypertensive treatment by RAS antagonists enalapril and valsartan.
In dTGRs, Ang II induced the expression of the CTGF in a time- and blood pressure-dependent
manner. This Ang II-induced expression of the CTGF co-located with marked perivascular
inflammatory response, cellular proliferation, vascular damage, and was associated with the
activation of the redox-sensitive transcription factors NF-κB and AP-1.
11
The pathological expression of the CTGF in dTGRs was prevented by AT1 receptor antagonist
valsartan. Suppression of the Ang II-mediated perivascular inflammatory response by an
antioxidant -lipoic acid or calcineurin inhibitors CsA and tacrolimus protected against the
overexpression of the CTGF in the dTGR. Dietary magnesium supplementation protected against
the induction of the CTGF gene in the dTGR. Additive therapeutic effects were found with
magnesium supplementation and tacrolimus treatment.
Taken together, these findings provide evidence that (1) high blood pressure induces the myocardial
expression of the CTGF gene (2) Ang II induces CTGF gene expression via AT1 receptor in a time-
and blood pressure-dependent manner (3) oxidative stress induces CTGF expression (4) systemic
magnesium balance regulates the expression of the CTGF.
12
1 INTRODUCTION
According to the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure (JNC), high blood pressure is defined as a blood pressure of >140/90 Hg
(Chobanian et al., 2003). In a great majority of adult patients no identifiable cause for hypertension
can be found. High blood pressure affects every fourth person in the industrialized countries. The
correlation between elevated blood pressure and cardiovascular complications has been clearly
demonstrated (for review, see Staessen et al., 2003).
Hypertension is among the most important risk factors for the development of several
cardiovascular diseases (atherosclerosis, coronary artery disease, myocardial infarction, stroke and
renal failure) (Chobanian et al., 2003) which necessitate a huge burden to medical care and
expences. The exact mechanisms contributing to the hypertension-induced end organ (blood
vessels, heart, kidney) damage remain obscure. The prevalence of morbid cardiovascular episodes
among the treated hypertensive patients remains higher when compared to the normal population
(for review, see Schiffrin, 2002a). This casts the question about the nature of hypertension-induced
end organ damage.
The pathological changes in the heart, blood vessels and kidneys of the hypertensive patients
include vascular remodeling, inflammation and vast connective tissue accumulation leading to
scarring of the involved organs (Mezzano et al., 2001; Dostal, 2001; reviewed by Williams, 2001).
Scarring of the heart or kidneys leads to the deterioration and ultimately to the failure of the organ
function. The accumulation of connective tissue is controlled by various growth factors. Much
attention has previously been focused on transforming growth factorβ1 (TGFβ1), a regulator of
collagen synthesis (Lijnen et al., 2000). Recently, however, a new growth factor, termed
“connective tissue growth factor” (CTGF), acting downstream from TGFβ1 was found (for review,
see Moussad and Brigstock, 2000). The expression of the connective tissue growth factor (CTGF),
which mediates the TGFβ1-induced collagen synthesis, has been noted to increase in the
atherosclerotic lesions, myocardial infarctions and renal fibrosis (Oemar et al., 1997; Ito et al.,
1998; Ohnishi et al., 1998). The regulation of the fibrosis-promoting CTGF gene is probably under
various vasoactive substances, growth factors and locally acting cytokines.
13
Currently, much attention is focused on angiotensin II (Ang II), the effector molecule of the renin-
angiotensin system (RAS). Ang II has an important role in the regulation of blood pressure,
vascular tone and body fluid balance (Weir and Dzau, 1999). The results of the recent Heart
Outcomes Prevention Evaluation (HOPE) study and others have shown that antagonizing the action
of Ang II has important protective effects on cardiovascular system, even independent of blood
pressure reduction (Yusuf et al., 2000; Schiffrin, 2002a). In addition to its role as a blood pressure
regulator, Ang II acts also as a growth factor contributing to cardiac hypertrophy and synthesis of
connective tissue in the heart, kidneys and blood vessels (Dostal, 2001). Ang II has been reported to
cause local inflammatory response by generating reactive oxygen species (ROS) and promote the
accumulation of connective tissue via the activation of TGFβ1 (Fakhouri et al., 2001; Sorescu and
Griendling, 2002).
The present study was designed to explore the role of the CTGF in the pathogenesis of
hypertension-induced end organ damage. In particular the influence of blood pressure and Ang II on
CTGF gene regulation was examined. As Ang II is a known promoter of hypertension and
cardiovascular complications, we used two hypertensive animal models with increased activity of
the renin-angiotensin system; namely, cyclosporine-treated spontaneously hypertensive rats (SHR)
on high sodium diet (Mervaala et al., 1997), and double transgenic rats harboring human renin and
angiotensinogen genes (dTGR) (Ganten et al., 1992). To further clarify the regulatory mediators of
the CTGF gene expression; we conducted intervention studies with antihypertensive drugs,
antioxidant, magnesium supplementation, as well as with anti-inflammatory immunosuppressive
drugs.
14
2 REVIEW OF THE LITERATURE
2.1 CONNECTIVE TISSUE GROWTH FACTOR (CTGF)
2.1.1 Structure and physiological functions
The term “connective tissue growth factor” (CTGF) was first introduced in 1991 by Bradham et al.
to describe a novel growth factor that was secreted by human endothelial cells in culture.
The CTGF gene belongs to the CCN (acronym of CYR61/CEF-10, CTGF/Fisp-12 and Nov) family
of growth factors (Moussad and Brigstock, 2000). The gene for human CTGF located in
chromosome 6q23.1 comprises five exons and four introns and has several regulatory elements such
as activator protein-1 (AP-1), nuclear factor kappa B (NF-κB), cyclic adenosine monophosphate
(cAMP), SMAD, and a unique transforming growth factor beta (TGF)-response element (TβRE)
in its promoter region (Figure 1) (Martinerie et al., 1992; Grotendorst et al., 1996; for review, see
Brigstock, 1999; Moussad and Brigstock, 2000). This element is different from the other reported
TGF -responsive elements and is not present in other genes regulated by TGF (Grotendorst et al.,
1996). Prior translation the CTGF mRNA is a target for posttranscriptional regulation by various
factors (Figure 2). The CTGF is a cysteine-rich peptide with four domains containing 349 amino
acids and a secretory signal peptide at the N terminus (reviewed in Gupta et al., 2000) (Figure 3).
The CTGF was first isolated from the endothelial cell culture (Bradham et al., 1991). Subsequently,
it has been detected in fibroblasts, cartilagenous cells and chondrocytes, cancer cell lines, smooth
muscle cells, renal podocytes and mesangial cells, hepatic sinusoidal cells, myofibroblasts,
pancreatic acinar and ductile cells, bronchoalveolar ductile cells, as well as in serum, tear fluid and
urine (Tamatani et al., 1998; Gupta et al., 2000; Sato et al., 2001; for review, see Blom et al., 2002;
Riser et al., 2003; van Setten et al., 2003).
15
Figure 1. Genomic structure of the CTGF with hypothesized regulatory elements in the promoter region (modified from Blom et al., 2002).
Ang II = angiotensin II AP-1 = activator protein-1
ROS = reactive oxygen species
cAMP = cyclic adenosine monophosphate TGF1 = transforming growth factor beta1
NF-κB = nuclear factor kappa B
T RE = transforming growth factor beta-response element
BCE-1 = basal control element-1
NO = nitric oxide
PGE2 = prostaglandin E2
IGF = insulin-like growth factor
promoter
intron
exon
I II III IV V
Genomic CTGF DNA signal sequence: secretion
IGF binding protein: IGF binding
von Willebrand factor: oligomerization
thrombospondin type I repeat: cell attachment
cysteine knot: receptor binding, dimerization
5’ 3’
Regulatory elements and hypothesized regulators of the promoter region
SMAD binding
AP-1 binding
Stretch responsive element
BCE-1 (T RE)
NF-κB binding site
SMADs
NF-κB
TGF 1
AP-1
Stretch
ROS
Thrombin
cAMP binding
Ang II
cAMP
NF-κB TGF 1
PGE2
NO
+
− + +
+ ++
+
−
+++
++
+
High glucose
+
16
Figure 2. Organization of the CTGF mRNA with hypothesized regulatory elements in the untranslated 3’ region (modified from Gupta et al., 2000).
Figure 3. Modular structure of the CTGF peptide (modified from Gupta et al., 2000).
Structure of translated CTGF peptide
Domain I Domain IVDomain IIIDomain II
Signal peptide
IGF binding
von Willebrand factor type C repeat
Hinge region
Thrombospondin type I repeat
C-terminal domain
N-terminal C-terminal
CTGF mRNA
3’ untranslated region
5’ 3’
Regulatory elements and hypothesized regulators of the untranslated 3’ region
RNA destabilizer
5’ 3’Signal peptide Domain I Domain II Domain III Domain IV
CYP1A1 silencer
IFN silencer
TNF silencer
TNF
−−IFN
−Shear stress
(If present, predisposes mRNA for degradation)
IFN = gamma interferon CYP1A1 = cytochrome P450 1A1 tumor necrosis factor alpha = TNF
17
The CTGF participates in several physiological processes including embryonic development and
differentiation, endochondral ossification, female reproductive tract function in the uterus and
ovary, wound healing, and angiogenesis (Moussad and Brigstock, 2000; Ivkovic et al., 2003).
The bioactivity of the CTGF is still under intense research. Depending on the cell types, CTGF has
been noted to promote mitosis, chemotaxis, stimulate apoptosis, angiogenesis, synthesis of
collagens, fibronectin and 5-integrin (Frazier et al., 1996; Gupta et al., 2000).
The mechanisms by which CTGF exerts its effects on target cells remain more or less unsolved.
Previous studies have demonstrated that adhesion of the endothelial cells, platelets, and fibroblasts
to CTGF is mediated through different integrin receptors. In the study by Babic et al. (1999),
murine CTGF was noted to modulate endothelial cell adhesion, migration, survival and
angiogenesis via 5β3 integrin receptor-dependent pathways. In addition, Segarini et al. (2001)
identified the low density lipoprotein receptor-related protein/2-macroglobulin receptor (LRP2) as
a receptor for CTGF in fibroblasts (Schober et al., 2002). By signaling through the integrins, a
mechanistic interpretation is provided for the chemotactic and mitogenic properties of the CTGF, as
well as for its functions in extracellular matrix (ECM) remodeling during angiogenesis and wound
healing (Blom et al., 2002).
After binding to its receptors, CTGF is presumably internalized into the endosomes, translocated to
the cytosol, phosphorylated by protein kinase C (PKC) and transported to the nucleus where it
stimulates the production of RNAs (Wahab et al., 2001).
2.1.2 Regulation of CTGF expression
Both in endothelial cells and smooth muscle cells the expression of the CTGF is induced by TGF1
(Hishikawa et al., 1999). Although several factors are capable of regulating CTGF gene expression,
it is generally believed that CTGF is transcriptionally activated primarily through TGFβ1. In
addition to TGFβ1, CTGF gene expression is also regulated by high glucose, tumor necrosis factor
α (TNFα), vascular endothelial growth factor (VEGF), cortisol, cAMP, coagulation protease
thrombin, prostaglandin E2 (PGE2), drugs such as iloprost and statins, as well as with
cytomegalovirus infection (Duncan et al., 1999; Murphy et al., 1999; Ricupero et al., 1999;
Abraham et al., 2000; Pereira et al., 2000; Suzuma et al., 2000; Howell et al., 2001; Stratton et al.,
2001; Eberlein et al., 2001; Inkinen et al., 2001). Furthermore, it has been recently shown that other
growth factors such as the platelet-derived growth factor (PDGF), epidermal growth factor (EGF),
and fibroblast growth factor (FGF) also activate CTGF gene expression at a transcriptional level
18
(Brigstock, 1999; Moussad and Brigstock, 2000). The intracellular pathways regulating CTGF are
still not clear. Very recently, Leask et al. (2003) reported that SMAD, PKC and Ras/MEK/ERK
(kinase) pathways are necessary for the TGF1-mediated induction of the CTGF promoter.
Induction of the CTGF promoter is antagonized by c-Jun or by MEKK1 (kinases), suggesting that a
proper balance between the Ras/MEK/ERK and JNK MAPK cascades is necessary for the induction
of the CTGF. Other important regulators of the CTGF might also be NF-κB, AP-1 and reactive
oxygen species (ROS), which are known mediators of inflammation. ROS stimulates the expression
of the CTGF through the activation of Janus kinases and AP-1 (Park et al., 2001).The role of the
NF-κB is more complex as, depending on the cell type, its activation has been shown to induce or
reduce the expression of CTGF (Blom et al., 2002). Interestingly, it has been previously noted that
the activity of the CTGF can be induced by varying the amount of tension (cyclic stretch and static
pressure) imposed on cells (Hishikawa et al., 2001; McCormick et al., 2001). This effect could be
explained by the presence of a stretch-responsive element in the CTGF promoter, which might
regulate the activity of the CTGF under conditions of mechanical stress (Blom et al., 2002).
2.1.3 Role of CTGF in pathological states
As a mediator of fibrotic processes, the expression of the CTGF has been noted to increase in
several pathological conditions involving inflammation and connective tissue accumulation
(Table 1). The expression of the CTGF has been reported to be practically absent in normal human
arteries, but highly enhanced in the intimal smooth muscle cells of atherosclerotic lesions and in the
myocardial infarcts (Oemar et al., 1997; Ohnishi et al., 1998). In the human kidney, the expression
of the CTGF has been found to be markedly increased in the glomerular and interstitial
inflammatory lesions with cellular proliferation and matrix accumulation e.g. IgA nephropathy,
chronic transplant rejection, crescentic glomerulonephritis, focal glomerulosclerosis, lupus nephritis
and membranoproliferative glomerulonephritis (Ito et al., 1998). Furthermore, the up-regulation of
the CTGF has been noted in numerous other pathological states and lesions (scleroderma, keloids,
dermatofibroma, malignant melanoma and other malignancies, chronic pancreatitis, hepatitis and
liver cirrhosis, Crohn’s disease and ulcerative colitis, pulmonary fibrosis and sarcoidosis) (Gupta et
al., 2000).
19
The role of the CTGF in inflammation-wound healing is evident. CTGF mediates the normal scar
formation in the lesion. Physiologically the activity of TGFβ1 and CTGF diminishes as the wound
heals and an adequate scar-formation is achieved. However, in pathologic conditions where the
inflammatory component remains abundant, the expression of the CTGF and hence the production
of collagens stay elevated. The chronic induction of the CTGF expression results in a pathologic
fibrosis of the involved organ and development of improper scars, like keloids (Igarashi et al.,
1996).
Table 1. Enhanced expression of CTGF in different diseases.
Scleroderma, eosinophilic fascitis, Dupuytren's contracture Igarashi et al., 1996
Desmoplastic malignant melanoma Kubo et al., 1998 Mammary carcinoma Frazier and Grotendorst, 1997
Chronic pancreatitis di Mola et al., 1999
Pancreatic cancer Wenger et al., 1999
Liver fibrosis, hepatitis C Paradis et al., 1999 Crohn’s disease, ulcerative colitis Dammeier et al., 1998
Idiopathic pulmonary fibrosis, sarcoidosis, asthma Allen et al., 1999; Burgess et al., 2003
Atherosclerosis Oemar et al., 1997
IgA nephropathy, crescentic glomerulonephritis, focal glomerulosclerosis, lupus nephritis, membranoproliferative glomerulonephritis and diabetic nephropathy
Ito et al., 1998; Wahab et al., 2001
Glioblastoma Pan et al., 2002
Ischaemic heart disease Chen et al., 2000
Cartilaginous tumors Shakunaga et al., 2000
Cerebral infarction Schwab et al., 2000
Disease Reference
Malignancies
Renal diseases
Cardiovascular diseases
Pulmonary diseases
Gastro-intestinal diseases
Dermatological diseases
Riser et al., 2003
2.1.4 Therapeutic approaches to prevent CTGF overexpression
During the last couple of years, accumulating evidence has postulated CTGF as an attractive target
for antifibrotic therapy. Although anti-TGFβ1 therapy has been shown to suppress the expression of
the CTGF, it is also pro-carcinogenic and pro-inflammatory in experimental models (Murphy et al.,
1999). Therefore the use of anti-CTGF therapy without dampening the growth-regulating effect of
TGFβ1 could be appropriate.
Recently, a neutralizing antibody and an antisense oligonucleotide to CTGF have been developed.
These molecules have been shown to block the TGF-stimulated collagen synthesis in various
preclinical models (Blalock et al., 2003). In clinical use, there are no specific drugs to prevent the
overexpression of the CTGF. The down-regulation of the CTGF has been noted with drugs having
diverse actions. Previously, Stratton et al. (2002) have shown that prostacyclin derivatives (iloprost)
are able to prevent the induction of the CTGF in fibroblasts and in patients with scleroderma
through the activation of PKA and blockade of the Ras/MEK/ERK signaling. Also, the cholesterol-
lowering drugs 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitors (statins)
have been shown to suppress the expression of the CTGF via inhibition of RhoA (Eberlein et al.,
2001). Moreover, Candido et al. (2002) have demonstrated that angiotensin convertase enzyme
(ACE) inhibitor therapy inhibits the CTGF overexpression in the aorta of the diabetic
apolipoprotein E-deficient mice.
2.2 HYPERTENSION-INDUCED END ORGAN DAMAGE
2.2.1 Lesions of the heart, vasculature and kidney
Cardiovascular and renal complications associated with hypertension have become one of the major
risk factors for disability and premature death in the industrialized countries. The hypertensive heart
diseases (left ventricular hypertrophy (LVH) and dilated cardiomyopathy (DCM)) resulting from
the hypertrophy of cardiac muscle fibers and/or deposition of extracellular matrix (fibrosis) can lead
to deterioration of cardiac function and ultimately to morbid and lethal cardiac events. Vascular
diseases (atherosclerosis and arteriosclerosis), originating from the thickening and stiffening of the
arteries, lead to hypoperfusion of different organs and can cause sudden death by occlusion of the
arteries (myocardial infarction, stroke) (for review, see Escobar, 2002). Strokes are strongly
associated with hypertension as hypertension-associated atheromatous plaques narrow brain
arteries, predisposing to local clot formation and ischaemia (for review, see Dickinson, 2003).
20
21
The renal damage, termed benign nephrosclerosis, can be characterized by a decline in arterial,
tubular and glomerular function (Bohle and Ratschek, 1982). The hypertension-associated renal
damage can lead to renal dysfunction and worsening of the hypertension. Non-insulin dependent
diabetes mellitus is the leading cause of end-stage renal disease requiring dialysis or kidney
transplantation in industrialized countries (Gerth et al., 2002; Keane et al., 2003). Diabetic
nephropathy with its resultant hypertension has exponentially increased the need and expences of
medical care in industrialized countries (Gerth et al., 2002; Williams et al., 2002).
2.2.1.1 Sympathetic nervous system in the pathogenesis of hypertension-induced end organ
damage
Sympathetic nervous system has a central role in controlling blood pressure and electrolyte balance.
Besides regulating adrenalin secretion from the adrenals, sympathetic nerves control renal blood
flow, sodium excretion and renin secretion (for review, see DiBona, 2000). Although the
importance of sympathetic nervous activation in the pathogenesis of essential hypertension is well
documented, the exact pathophysiology of the sympathetic nervous dysfunction present remains to
be elucidated. In addition to the increased rate of sympathetic nerve firing there are several
explanations for the increased spillover of noradrenaline to plasma, providing a neurogenic basis of
hypertension (reviewed by Esler et al., 2001). Sympathetic nervous system overactivity is present in
a proportion of patients with essential hypertension, principally in younger ones with hypertension
in its developmental phase (Esler et al., 1989). Sympathetic stimuli regulate the volume of
myocytes, proliferation of smooth muscle cells and ECM production, and thereby contribute to
cardiac and vascular remodeling (Hu et al., 1999; O’Gallaghan and Williams, 2002; Schlaich et al.,
2003). Previously Aggarwal et al. (2002) have demonstrated an elevated noradrenergic activity in
human congestive heart failure (CHF) and a positive correlation between this and the level of
whole-body noradrenaline spillover. Moreover, LVH has been shown to associate with increased
sympathetic activity largely confined to the heart, suggesting that increased cardiac noradrenaline
release is related to the development of LVH (Schlaich et al., 2003). As enhanced levels of
sympathetic activity promote hypertension, cardiac arrhytmias and increased activity of RAS,
treatment with prazosin, clonidine, ganglionic blockers, reserpine and -adrenoceptor blockers have
been widely used in the treatment of cardiovascular diseases.
22
2.2.1.2 Involvement of the mechanical factors
Heart and vasculature
In the heart, arterial hypertension causes myocardial hypertrophy. When enhanced hemodynamic
load is imposed on the left ventricle for a prolonged time the physical stress results in hypertrophic
responses such as the activation of the phosphorylation cascades of many protein kinases,
expression of specific genes and an increase in protein synthesis ultimately leading to the
impairment of the cardiac function and malignant enlargement of the myocardium (pathological
hypertrophy) (Wikman-Coffelt et al., 1979). During this pathological process, the production of
vasoactive peptides such as Ang II, is increased which plays a critical role in the induction of
cardiohypertrophic responses (for review, see Zou et al., 2002).
Along with the enlargement of cardiomyocytes, there are alterations in the ECM which provides the
supportive structure for the myocytes and capillaries (for review, see Weber, 2001). In the process
of cardiac hypertrophy, fibroblasts enhance their synthesis of fibrillar collagens, which leads to the
accumulation of collagens in the interstitium, and around the myocardial arteries. Subsequently this
leads to the stiffening of the myocardium and deterioration of cardiac contractile function (Weber,
2001). Although it is difficult to separate the effects of mechanical and hormonal stimuli, in vitro
studies support a role for mechanical stress in regulating the cardiac hypertrophy. It has been
previously shown that the stretching of the muscle fibre leads to enhanced synthesis of contractile
proteins (Wikman-Coffelt et al., 1979). Even the stretch directed towards a single cardiac cell
evokes the activation of hypertrophy-associated genes (c-fos, c-jun, c-myc, -actin, β-myosin)
(Sadoshima et al., 1992). Besides the genes associated with cardiomyocyte hypertrophy, the
synthesis of cardiac collagens and eventually cardiac fibrosis is also regulated by mechanical
stimuli (Carver et al., 1991).
Increased wall tension due to pressure overload serves as a growth promoting stimulus for smooth
muscle cells (VSMC) within the vessel wall. This leads to the proliferation and hypertrophy of the
VSMC. In addition, activated smooth muscle cells secrete components of the ECM (collagens)
(Sumpio et al., 1988). Together with the concomitant endothelial dysfunction this leads to the
stiffening of the arterial structure, increased peripheral resistance and weakened responsiveness to
vasorelaxing factors (arteriosclerotic changes) (Shepherd, 1990; reviewed by Jeffery and Morrell,
2002).
23
Kidney
The importance of the kidneys in regulating blood pressure was comprehensively reviewed in 1972
by Guyton et al.. Kidneys regulate blood pressure and systemic sodium and fluid balance via the
action of renin, Ang II, aldosterone and vasopressin. A high intake of sodium can promote “salt-
sensitive” hypertension and it has been previously shown that a high sodium intake predicts
mortality and risk of coronary heart disease, independent of other cardiovascular risk factors,
including blood pressure (Tuomilehto et al., 2001). As the kidneys have a sophisticated auto-
regulatory system for the adjustment of the intrarenal blood flow, it seems probable that the renal
lesions accompanying hypertension are not a direct consequence from the pressure overload.
Instead the increased renal vascular resistance seems to be present already at the early stages of
hypertension (reviewed by Ruilope et al., 1994). Therefore, it seems possible that in humans,
arterial hypertension may sometimes be a consequence from the alterations in the renal circulation
or nephron number (Keller et al., 2003). Support to this notion comes from the transplantation
studies, where the “hypertensive kidney” has been transplanted into normotensive animals which
thereafter become hypertensive (Dahl and Heine, 1975).
2.2.1.3 Involvement of the hormonal factors and inflammation
The prevalence of pressure-overload cannot solely explain the occurrence of organ lesions in the
hypertensive patients, as the frequency of morbid cardiovascular episodes among the treated
hypertensive patients remains higher when compared to the normal population. Recently, much
attention has been focused on the hormonal mechanisms in the development of the end organ
damage. With ever-increasing data from numerous studies, hormonal factors and inflammatory
reactions are today considered as the key effectors in contributing to the development of
myocardial, vascular and renal lesions associated with hypertension (Figure 4) (Ridker et al., 1997;
for review, see Lagrand et al., 1999). Very recently, in the Framingham study, it was shown that
increases in the serum inflammatory markers, particularly elevated interleukin-6, were associated
with increased risk of congestive heart failure in a patient population without prior myocardial
infarction (Vasan et al., 2003).
24
Figure 4. Simplified scheme of events leading from vascular injury to fibrosis (modified from Franklin, 1997).
Heart and vasculature
The most common injury to the heart is the myocardial infarction. During the first weeks after a
massive infarction, the myocardium is susceptible to rupture. The function of the repair process is to
maintain the structural integrity. The replacement of the contractile tissue by scar leads to impaired
myocardial function by decreasing the myocardial contractility. In hypertensive heart disease,
resistance arteries (including coronary vessels) undergo remodeling processes. Coronary arteries
develop accumulation of collagen in the adventitial layer (perivascular fibrosis) where bundles of
collagen extend also into the interstitial areas of the myocardium (interstitial fibrosis) (Silver et al.,
1990). The atherosclerotic lesions develop within several years and are characterized by smooth
Vascular injury
diabetes traumahypertension myocardial
infarction
Activation of the inflammatory cells
Release of cytokines, growth factors and matrix proteins
Activation of the mesenchyme-derived cells
Proliferation, synthesis of extracellular matrix
Vascular fibrosis
25
muscle cell proliferation, chronic inflammatory reaction and deposition of lipid and matrix in the
subintimal space.
Kidney
Depending on the nature of the lesion, the healing process in the kidney results in fibrosis of the
affected glomeruli and interstitium. The hypertension-associated lesions usually comprise damage
to the afferent arteries with the thickening of the medial layer with connective tissue. In more severe
cases the afferent arteries have marked concentric hypertrophy and/or fibrinoid necrosis. In
association with arterial damage there is often glomerular (glomerular ischaemia,
glomerulosclerosis) and tubular (tubulo-interstitial fibrosis) lesions (Bohle and Ratschek, 1982).
The inflammation-healing process
The repair process of the affected organ begins immediately after injury and thus overlaps with the
inflammatory response. It is through continuum of inflammatory reactions and deposition of ECM
that the injuries are healed. The connection between inflammation and fibrosis can be seen in the
early phases of embryonic development when there is no inflammatory response to an injuring
stimulus. The healing occurs by proliferation of the cells surrounding the lesion and no fibrosis
occurs.
Whether the injuring stimulus has been a myocardial infarction following a coronary artery
occlusion or an effect by an endogenous hormone, the healing process eventuates in fibrous tissue
formation (Figure 4). On the first stage of the inflammatory phase, platelet-derived cytokines
attract cells from the leukocyte axis and polymorphonuclear neutrophilic leukocytes (PMN)
infiltrate the lesion. These cells appear within hours from the injury and their function is to remove
the cellular debris from the wound. The infiltration of PMN is soon followed by the accumulation
of monocytes/macrophages which remove debris from the lesion and release pro-inflammatory
cytokines and interleukins; colony-stimulating factors (GM-CSF), growth factors (TGFβ1,
thrombospondin-1 (TSP-1), PDGF, FGF) and ROS. Lymphocytes possess the ability for antigen-
specific recognition and they control the function of other leukocytes. B lymphocytes participate in
the humoral response by secreting various antibodies and T lymphocytes, in turn, regulate the
cellular inflammatory response. In addition to the cells specific to the injured tissue, the stromal
cells (fibroblasts, smooth muscle cells, endothelial cells and inflammatory cells) have a major role
in repair. In response to growth factors released by other cells, fibroblasts begin to proliferate and
secrete components of the ECM. The fibroblast-derived collagens assemble to form the fibrillar
network that eventually becomes the scar of the damaged area.
26
2.2.1.3.1 Angiotensin II
From the large number of growth factors involved in the regulation of inflammation and
regeneration, much attention has recently been paid on Ang II.
Ang II is the active effector of the RAS. Ang II regulates blood pressure, plasma volume and the
activity of the sympathetic nervous system. It has also a fundamental role as a growth factor in
myocardial, vascular and renal remodeling (for review, see Touyz and Schiffrin, 2000). Originally
described as a systemic humoral system, Ang II is currently known to be produced also in several
tissues by the activation of local RAS (for review, see Bader et al., 2001). Under conditions of salt
or volume depletion or sympathetic activation, the protease renin, derived from the macula densa of
the juxtaglomerular apparatus, cleaves the liver-derived peptide angiotensinogen to form
angiotensin I (Ang I). The main effector of the RAS, Ang II, is then formed by the ACE. ACE
exists usually in an endothelium-bound form with particularly high concentrations in the lung
(Bader et al., 2001). In addition to ACE, Ang II can be formed by other enzymes. Generation of
Ang II has been noted to occur via the activation of chymase, cathepsin G and tonin (reviewed by
Dzau et al., 1993). Local (tissue) RAS is activated under pathophysiological conditions where the
synthesized Ang II appears to contribute to altered tissue function and morphology (Hirsch et al.,
1990). Furthermore, in some tissues, locally formed Ang II may exceed the importance of
circulating Ang II (Navar et al., 1996). Ang II exerts its effects via binding to its receptors located
in the cell surface. Two main subtypes of Ang II receptors have been cloned, described and
classified, namely the G-protein-coupled AT1 and AT2 receptors (Timmermans et al., 1993). Two
other subtypes of Ang II receptors have also been described but are not yet included in the
definitive classification of the mammalian AT receptors. To date, AT1 receptors have been shown to
mediate most of the physiological actions of Ang II, and this subtype is predominant in the control
of Ang II-induced vascular functions (Touyz and Schiffrin, 2000). In contrast to the AT1 receptor,
the physiological role of the AT2 receptor remains elusive. It has been suggested that the AT2
receptor counteracts the Ang II-induced effects of the AT1 receptor (Nakajima et al., 1995;
reviewed by Siragy and Carey, 2001). Although the main function of smooth muscle cells is
vasoconstriction, it has also become evident that the Ang II-induced stimulation of the AT1
receptors has a major role in the proliferation of VSMC and fibroblasts, deposition of ECM and
inflammation (Dostal, 2001; Mezzano et al., 2001).
27
Signaling events generated by Ang II
Upon binding to its receptor, Ang II causes an increase in the intracellular free Ca2+, Na+ and an
efflux of Mg2+ (Touyz and Schiffrin, 2000). Ang II activates growth promoting signal pathways
(Janus kinases, MAP-kinases, calcineurin and p70S6-kinase) and mediators of cell migration (focal
adhesion kinase) and regulators of ROS and inflammation (nicotinamide adenine dinucleotide
phosphate (NADPH) oxidases, NF-κB, AP-1) (Schmelzle and Hall, 2000; Molkentin and Dorn,
2001; Liu et al., 2003). The Ang II-mediated activation of intracellular kinases leads to the
induction of early growth-response genes and regulation of the vascular and cardiac growth,
remodeling and repair (reviewed by Berk and Corson, 1997).
The calcium-calmodulin, Ser/Thr protein phosphatase calcineurin and its downstream
transcriptional effector nuclear factor of activated T cells (NFAT) play pivotal roles in the immune
response. Activation of calcineurin leads to dephosphorylation and nuclear translocation of NFAT
and regulation of several inducible genes in T cells. Recently, a role for calcineurin-dependent
pathways in the signal transduction of cardiac growth has been postulated. Stimulation of
calcineurin is capable of driving cardiac hypertrophy, heart failure, and death in experimental
animal models (Molkentin et al., 1998; reviewed by Molkentin, 2001). Ang II stimulates the
hypertrophy and proliferation of cardiomyocytes and cardiofibroblasts through the induction of
calcineurin thus suggesting a role for calcineurin-dependent pathways in the pathogenesis of Ang
II-induced cellular hypertrophy and proliferation (Fu et al., 1999).
Previous studies have provided compelling evidence that Ang II controls the process of cardiac and
vascular hypertrophy also via AT1 receptor-mediated activation of p70S6-kinase which regulates
the cellular response to nutrients, organization of the actin cytoskeleton, membrane traffic, protein
degradation, PKC signaling, ribosome synthesis and possibly, mechanisms of cancer (reviewed in,
Schmelzle and Hall, 2000). In addition, p70S6-kinase has a central role in inflammatory reactions
(Giasson and Meloche, 1995; Takano et al., 1996; Lehman et al., 2003).
Ang II and inflammation
A link between the RAS and inflammation-wound healing has been previously noted. Ang II
stimulates the proliferation of lymphocytes and regulates their activation through AT1 receptor-
mediated induction of calcineurin phosphatase (Nataraj et al., 1999). Chronic activation of RAS,
resulting in a permanent elevation in plasma and tissue Ang II, leads to perivascular inflammation
and fibrosis, vascular remodeling, myocyte necrosis and subsequent scar formation, even in the
absence of hypertension (Figure 5) (Ratajska et al., 1994; Mervaala et al., 1999; Weber, 2001).
Ang II stimulates NADPH oxidase to produce ROS such as superoxide anions and hydrogen
28
peroxide, which participate in the regulation of VSMC growth, apoptosis of cardiomyocytes,
induction of vascular inflammatory response, impairment of endothelial-dependent vascular
relaxation, atherosclerosis and pathogenesis of mechanical stress-induced cardiac hypertrophy
(Figure 5) (Aikawa et al., 2001; Aikawa et al., 2002, reviewed by Griendling et al., 2000). Our
group has previously shown that Ang II-mediated inflammatory reaction in the heart, kidney and
vasculature, characterized by leukocyte infiltration and vascular adhesion molecule overexpression
are due to Ang II-induced ROS formation and activation of the redox-sensitive transcription factors
NF-κB and AP-1 (Müller et al., 2000a). Moreover, we have shown that Ang II controls the
migration of mature dendritic cells even by blood pressure-independent mechanisms and activates
monocytes/macrophages even in the uninjured areas (Mervaala et al., 1999; Müller et al., 2002).
Figure 5. Different mechanisms of Ang II-induced vascular inflammation (modified from Ruiz-Ortega et al., 2001)
Secretory products Reactive oxygen species
O2-, H2O2, OH-
Cytokines and growth factors Interleukins, TNF , MCP-1, TGF , PDGF, FGF, G-CSF, GM-CSF, CTGF
Matrix proteins Fibronectin, thrombospondin
Enzymes Proteases, collagenases, elastase, ACE
Activated monocyteAdhesion and transmigration
Secreting monocytes
Ang II (Promotes chemotaxis, activation, adhesion and transmigration)
Ang II
Endothelial cells
Smooth muscle cells
Ang II = angiotensin II ACE = angiotensin converting enzyme
FGF = fibroblast growth factor
GM-CSF = granulocyte-macrophage colony-stimulating factor
G-CSF = granulocyte colony-stimulating factor
CTGF = connective tissue growth factor MCP-1 = monocyte chemoattractant protein-1 PDGF = platelet-derived growth factor
TNF = tumor necrosis factor alpha TGF = transforming growth factor beta
Circulating monocyte
Secretory products
29
Ang II-mediated induction of growth factors
Ang II has a major role in regulating the cardiac and renal growth and structure. In addition to the
pressure-induced mechanical factors, hypertrophy of the heart is also governed by the growth-
promoting action of Ang II. Similarly, a number of kidney diseases, and their progression to the
end-stage renal disease, are driven, in part, by the effects of Ang II. Ang II is a powerful mitogen
and an ECM promoting factor for many cell types. It increases DNA synthesis, promotes cell-cycle
progression and up-regulates the expression of growth factors such as endothelin-1, TGFβ1, PDGF,
and FGF which induce cellular hypertrophy, hyperplasia and production of the ECM (Stirling et al.,
1990; Gibbons et al., 1992; Nakahara et al., 1992; Kaiura et al., 2000). The Ang II mediated
production of collagen and fibronectin in the heart and kidney is primarily mediated by TGF1
(Kagami et al., 1994; Everett et al., 1994; Funck et al., 1997).
TGFβ is one of the most potent profibrotic stimuli to fibroblasts. TGF participates in the normal
development, wound repair, and several pathological processes including cardiac, renal and liver
fibrosis, development of atherosclerosis, and arteriosclerosis (for review, see Border and Noble,
1994; Ihn, 2002). At the site of tissue injury, TGF (released from infiltrating lymphocytes,
platelets, activated macrophages, injured myocytes and fibroblasts) is first secreted in a latent form.
The latent form is then activated by other peptides, such as TSP-1. Activation of the TGF1
increases the expression of collagen types I, III, VI, VII and X and fibronectin (for reviews, see
Massague, 1990; Govinden and Bhoola, 2003). The production of the ECM is further enhanced by
the inhibitory effect of the TGF on matrix degradation by decreasing synthesis of proteases and
increasing levels of protease inhibitors (Massague, 1990; Govinden and Bhoola, 2003). The
functional importance of the TGF in wound healing can be seen after myocardial infarction.
Weeks after infarction the TGF receptor density is markedly increased in both the infarcted and
noninfarcted myocardium and it is anatomically coincident with sites of fibrosis (Sun et al., 1998).
Besides participating in the reparative wound healing response, TGF also controls the fibrosis
caused by myocardial pressure-overload. As Ang II is known to cause mechanical stress
(hypertension), fibrosis via the activation of the TGF1, perivascular inflammation, inflammatory
end organ damage characterized by an abundance of leukocytes and activation of the inflammatory
mediators (NF-κB, AP-1), the involvement of Ang II in regulating the expression of the CTGF
deserves further notice.
30
2.3 ANIMAL MODELS USED IN THE PRESENT STUDY
2.3.1 Spontaneously hypertensive rat (SHR) (Study I)
The SHR is the most widely used animal model for human hypertension. In the SHR the arterial
hypertension and essential human hypertension share many similarities in the pathogenic
mechanisms (Trippodo and Frohlich, 1981). The SHR strain was developed in 1963 by Okamoto
and Aoki. The SHR has been shown to possess a genetic susceptibility to (salt-sensitive)
hypertension (St. Lezin et al., 1997). Blood pressure in the SHR rapidly increases during the first 3-
4 postnatal months after which it stabilizes at an elevated level. The SHR has an enhanced
sympatho-adrenal drive and develop functional and structural vascular lesions (impaired
vasodilatation, vascular remodeling) (Trippodo and Frohlich, 1981; Koller and Huang, 1994). To
examine the pathogenesis of the CsA-induced hypertension and end organ damage, we have
developed an animal model, i.e. the CsA-treated SHR on high sodium diet in which magnesium
deficiency as well as increased RAS activity is involved in the pathogenesis of the CsA toxicity
(Mervaala et al., 1997; Lassila et al., 2000).
2.3.2 Double transgenic rat harboring human renin and angiotensinogen genes (dTGR)
(Study II, III, IV)
The transgenic rat-strain carrying the human angiotensinogen TGR-(hAOGEN) and human renin
TGR-(hREN) genes was originally developed for the study of human renin inhibitors which
ordinarily do not function in rats. The human components of the RAS in the dTGR do not interact
with the endogenous rat RAS (Ganten et al., 1992; Bohlender et al., 1997). Hypertension, vascular
inflammation and end organ damage in the dTGR are due to increased Ang II synthesis by the
human components of the RAS. The development of the myocardial, renal, and vascular damage in
the dTGR is age-dependent. In fact, immediately after weaning at the age of 3-4 weeks, myocardial
and renal tissue morphology, assessed by light microscopy, are indistinguishable between the dTGR
and the normotensive SD rat. In contrast, marked inflammatory cell recruitment, mainly consisting
of monocytes and macrophages, as well as an up-regulation of the intercellular adhesion molecule-1
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and the exctracellular matrix component
fibronectin, are already present at an early age of the dTGR (Mervaala et al., 1999; Müller et al.,
2000b). These findings have been interpreted as follows: Ang II triggers inflammatory response and
31
exerts direct pro-inflammatory effects by blood pressure-independent mechanisms related to the
activation of the redox-sensitive transcription factors NF-κB and AP-1 as well as oxidative stress
(Müller et al., 2002).
2.4 COMPOUNDS USED IN THE PRESENT STUDY
2.4.1 Enalapril (Study I)
ACE inhibitors are nowadays widely used in the treatment of essential and renovascular
hypertension. Numerous large clinical studies have shown long-term reductions in the incidence of
the myocardial infarction, stroke, cardiac arrest, heart failure, and atherosclerosis in patients treated
with ACE inhibitors (Sleight, 2002).
ACE inhibitors prevent the ACE-mediated conversion of angiotensin I to angiotensin II. Thus,
inhibition of the ACE diminishes the formation of Ang II. This in turn, leads to vasodilatation and a
decrease in blood pressure. In addition, the blockade of the ACE promotes the bioavailability of
vasodilatating substance bradykinin. As Ang II is an important regulator of renal blood flow,
sodium homeostasis and mineralocorticoid aldosterone, the ACE inhibition promotes natriuresis by
increasing renal blood flow, sodium excretion and by preventing the action of aldosterone. In
addition to the antihypertensive effect, ACE inhibitors have been shown to diminish the
inflammatory response associated with the end organ damage. Therefore ACE inhibitors are also
used to prevent the progressive cardiovascular and renal damage in diabetes mellitus. The most
common adverse effects of the ACE inhibitors: dizziness, headache and cough are usually well
tolerated (Gradman et al., 1995).
2.4.2 Valsartan (Study I, II)
Valsartan belongs to the family of the Ang II receptor AT1-antagonists. AT1 receptor antagonists
are currently used in the treatment of essential hypertension. In clinical trials, valsartan has been
shown to reduce symptoms, enhance the quality of life and lessen morbidity and mortality in
patients (for review, see Manohar and Pina, 2003). In patients who cannot tolerate ACE inhibitors
because of angioedema or severe cough, an AT1 receptor antagonist can be succesfully used as an
alternative. Recently, valsartan has been approved as a treatment of heart failure in patients who
cannot be maintained on an ACE inhibitor therapy (Manohar and Pina, 2003).
32
The antihypertensive and anti-inflammatory effects of valsartan resemble closely the ones seen with
the ACE inhibitor enalapril. By specifically blocking the AT1 receptor, valsartan does not directly
affect the synthesis of Ang II. In contrast, it prevents the action of Ang II at the receptor level. As it
has been hypothesized that the AT2 receptor-mediated action of Ang II could have some beneficial
effects, including anti-fibrotic action, the blockade of only one subtype (AT1) of the Ang II
receptors might have additional therapeutic effects. The most common adverse effects associated
with valsartan therapy include: headache, dizziness and tiredness. As the RAS plays a crucial role in
the normal renal development neither the ACE inhibitors nor the AT1 receptor blockers can be used
during gestation (for review, see Guron and Friberg, 2000).
2.4.3 -Lipoic acid (Study III)
In humans, lipoic acid is currently used to improve the glucose effectiveness, and to prevent the
progression of diabetic neuropathy. Its efficacy has also been examined in the treatment of various
neurological disorders (for review, see Ziegler et al., 1999). Lipoic acid is a sulfur-containing
coenzyme required for the mitochondrial dehydrogenase reactions leading to the ATP formation.
Lipoic acid and the reduced form, dihydrolipoate, are potent natural antioxidants. Lipoic acid reacts
with superoxide, hydroxyl radicals, hypochlorous acid, peroxyl radicals, and singlet oxygen
(Carreau, 1979; Packer et al., 1995; Moini et al., 2002). It has been previously reported that dietary
lipoic acid supplementation decreases oxidative stress, ameliorates hypertension and protects
against renal and vascular injuries in various animal models (Kocak et al., 2000; Suh et al., 2001).
Treatment with lipoic acid is usually well tolerated without any major adverse effects (Evans et al.,
2002).
2.4.4 Cyclosporine A (CsA) (Study I, II)
The calcineurin inhibitor CsA is a fungal cyclic polypeptide, which has been widely used to prevent
rejection of organ transplants. After its introduction, CsA has increased graft survival and decreased
patient mortality significantly compared to more conventional immunosuppressives (Merion et al.,
1984). Moreover, the use of CsA to treat several autoimmune diseases has increased during the
recent years.
CsA was the first T lymphocyte selective drug to inhibit lymphocyte function without concomitant
myelosuppression. CsA binds to cyclophilin to inhibit the phosphatase calcineurin, and thereby
prevents the dephosphorylation of NFAT and production of inflammatory cytokines, particularly
33
interleukin-2 (IL-2), which is critical for T lymphocyte proliferation and maturation, and interferon
γ (IFN γ) which is critical for macrophage activation (Liu et al., 1992).
Despite its beneficial effect on the long-term graft survival, the mortality due to cardiovascular
diseases and renal failure is greater among the CsA-treated graft recipients than among the normal
population. This is probably a consequence of the severe and common adverse effects of the CsA,
hypertension and nephrotoxicity which could be mediated by the CsA-induced activation of RAS
(Julien et al., 1993; for review, see Textor et al., 1994).
2.4.5 Tacrolimus (FK506) (Study IV)
The calcineurin inhibitor tacrolimus is a macrolide which effectively prevents rejection of
organ transplants with a concomitant decrease in patient morbidity and mortality (Margreiter,
2002).
Similarly to CsA, tacrolimus also inhibits the activity of calcineurin and NFAT and hinders the
production of inflammatory cytokines IL-2 and IFN γ. Although this occurs via different pathways
(CsA binds to cyclophilin and tacrolimus binds to FK506 binding protein (FKBP)), the inhibition of
calcineurin produces similar pharmacologic effects with both drugs. Clinical studies suggest similar
graft and patient survival with either CsA or tacrolimus. The relative frequency of chronic rejection
in patients treated with tacrolimus versus CsA has not been shown to differ. The side-effect profile
of CsA and tacrolimus are more or less similar. However, certain side-effects, such as gingival
hyperplasia, hirsutism, hyperlipidemia and hypertension are more commonly noted with CsA,
whereas tremor and glucose intolerance are associated more often with tacrolimus (for review, see
Morales et al., 2001; Hood, 2002).
2.4.6 Everolimus (SDZ RAD) (Study II)
The mammalian target of rapamycin (mTOR) inhibitor everolimus is a macrolide
immunosuppressant used to prevent the inflammatory graft-rejection among the organ transplant
recipients. It has been used alone and, more commonly, with calcineurin inhibitors. The synergistic
effect of the everolimus and calcineurin inhibitors have shown low rates of acute rejection,
improved rates of patient and graft survival, and better renal function in organ transplant recipients
(for review, see Nashan, 2002a).
34
Everolimus is a proliferation signal inhibitor that blocks growth factor-driven proliferation of the T
cells, B cells and VSMC by inhibiting the activation of the p70S6-kinase. Everolimus has been
shown to reduce acute rejection, limit the CsA-induced nephrotoxicity, protect against
cytomegalovirus infections, and inhibit vascular remodeling (for review, see Nashan, 2001; Nashan,
2002b). Previous studies have provided strong evidence that the p70S6-kinase plays an important
role also in Ang II-induced protein synthesis, vascular and cardiac hypertrophy, and possibly,
inflammatory response (Giasson and Meloche, 1995; Takano et al., 1996). The most common
adverse effects of the everolimus are thrombocytopenia and hyperlipidemia but not hypertension.
2.4.7 Magnesium (Study IV)
In epidemiological studies, altered magnesium balance has been linked to the prevalence of
hypertension and hypertensive heart diseases. Some subgroups of hypertensive patients (e.g.
African-Americans, the elderly, patients with insulin resistance or pre-eclampsia) have a high
incidence of altered magnesium metabolism and pre-eclamptic and eclamptic patients are
consistently treated with magnesium (Touyz et al., 1987; Touyz et al., 1992; Touyz, 2003). In
addition, a relationship has been noted between Ang II, magnesium and blood pressure (Touyz and
Schiffrin, 2000). Magnesium has a multitude of functions in the cardiovascular system. Magnesium
regulates contractile proteins, transport of other cations (calcium, sodium and potassium), DNA and
protein synthesis, cell replication, and oxidative-phosphorylation (Touyz, 2003). Serum magnesium
is regulated within a range of 0.7-1.1 mmol/l, and the current recommended daily allowance (RDA)
for magnesium is 400mg/d (National Public Health Institute, Finland, 1998).
In experimental models of hypertension, hypomagnesemia causes elevation in blood pressure and
increased reactivity to vasoconstrictors (Miyagawa et al., 2000). Thus, it may be possible that Ang
II-dependent hypertension is associated with cardiovascular effects of hypomagnesemia. It has been
recently demonstrated that Ang II promotes magnesium efflux and decreases intracellular and
serum magnesium possibly by stimulating the Na+/Mg2+ exchanger in VSMC. In addition,
imipramine and quinidine, inhibitors of Na+/Mg2+ exchanger have been shown to attenuate the Ang
II–induced hypertension in rats (Touyz and Yao, 2003).
35
3 AIMS OF THE STUDY
Since its discovery in 1991, CTGF has received growing attention as a mediator of fibrotic
processes. Intense research by various groups has provided much information about the regulation
and nature of the CTGF. The enhanced expression of the CTGF has been linked to several diseases
associated with inflammation and connective tissue accumulation. However, the role of the CTGF
in the pathogenesis of the hypertension-induced end organ damage and its connections to RAS has
not yet been established.
By using CsA-treated SHR on high sodium diet and dTGR as experimental animal models,
the specific aims of the study were:
• To investigate whether the arterial hypertension promotes myocardial
CTGF gene expression.
• To examine whether Ang II regulates CTGF gene expression.
• To evaluate whether the antagonists of the RAS protect against the induction of the CTGF.
• To investigate the effects of immunosuppression and antioxidant therapy on the CTGF gene
expression.
• To examine whether magnesium supplementation ameliorates Ang II-induced myocardial
damage and CTGF overexpression.
36
4 MATERIALS AND METHODS
4.1 EXPERIMENTAL ANIMALS
In Study I, 48 male spontaneously hypertensive rats (SHR) and 8 Wistar-Kyoto (WKY) rats (Harlan
Sprague Dawley, Indianapolis, IN, USA) aged 7-9 weeks at the beginning of the experiment were
used.
Studies II, III, and IV included 120 male 3-4 week-old double transgenic rats harboring human
renin and angiotensinogen genes (dTGR) (RCC, Füllinsdorf, Switzerland) and 40 age-matched
normotensive Sprague Dawley rats (SD) (M&B, Ejby, Denmark).
The rats were housed in a standard laboratory facility (temperature 22-24°C, a 12-hour light-dark
cycle). The rats had free access to tap water and feed during the experiment.
4.2 EXPERIMENTAL DIETS AND DRUG TREATMENTS
In Study I, rats were placed on high-sodium diet during the treatment (sodium 2.6%, magnesium
0.2%, potassium 0.8%, calcium 1.0%, phosphorous 0.75%) The food was prepared by adding
sodium chloride to the commercially available rat chow (R36, Finnewos Aqua, Helsinki, Finland).
In Studies I-IV, enalapril (30 mg/kg/d. Leiras Ltd, Turku, Finland), valsartan (3 and 30 mg/kg/d.
Novartis Ltd, Basel, Switzerland), -lipoic acid (350 mg/kg/d. Sigma Aldrich Finland, Helsinki,
Finland), and magnesium (0.6 % of the dry weight of the feed) were mixed in the standard food to
produce the planned daily doses. Normal rat chow served as the control diet. Drug concentration in
the chow was calculated based on the fact that food consumption of an adult rat is approximately
20-25 g/day. The actual intake of drugs was verified in the metabolic studies.
Cyclosporine (2 and 5 mg/kg/d. Novartis Ltd, Basel, Switzerland) and tacrolimus (1 mg/kg/d.
Fujisawa Europe, Munich, Germany) were administered subcutaneously (I, II, IV). Everolimus (2.5
mg/kg/d. Novartis Ltd, Basel, Switzerland) was administered by gavage (II).
37
4.3 MEASUREMENT OF BLOOD PRESSURE
Systolic blood pressure and heart rate from the pretrained rats were measured by using a tail-cuff
blood pressure analyzer (Apollo-2AB Blood Pressure Analyzer, Model 179-2AB, IITC Life
Science, Woodland Hills. CA., USA). Before the measurement, the rats were kept at +30°C for 30
min to enable the pulsations of the tail artery to be detected. Systolic blood pressure was calculated
from the arithmetic mean of three consecutive results without disturbances in the signal.
4.4 METABOLIC STUDIES
During the last week of the experiments (I, III, IV) (weekly in Study II), the rats were housed
individually in metabolic cages. The consumption of food and water was measured, and the
estimated intake of drugs was calculated. Urine was collected over a 24-hour period, urine volumes
were measured and samples stored at -80°C until the biochemical determinations were performed.
4.5 COLLECTION OF THE SAMPLES
At the end of the experiments, the rats were made unconscious with CO2/O2 (70%/30%; AGA,
Riihimäki, Finland) and decapitated. In Study II, an additional group of SD rats was sacrificed at
the age of 4 weeks, and dTGR rats at the age of 4, and 5.5 weeks.
Blood samples were taken into chilled tubes with or without an anticoagulant (EDTA 4.5 mM).
Plasma and serum were stored at -80°C until the biochemical determinations were performed. The
heart and kidneys (I-IV) and pulmonary artery (II) were excised, washed with ice-cold saline,
blotted dry and weighed. Tissue samples for mRNA detection were snap-frozen in liquid nitrogen
and samples for immunohistochemistry in isopentane (-35°C), then all were stored at -80°C until
assayed. Samples for conventional morphology, immunohistochemistry and in situ hybridization
were fixed with 10 % formaline and processed in paraffin with routine techniques.
4.6 HISTOLOGY
4.6.1 Sample preparation
The samples for histology were fixed with 10 % formaline for 24-48 hours and processed in
paraffin through ascending ethanol concentrations and xylene. Sections (3-5 m) were cut with
38
a microtome, rehydrated through xylene and descending ethanol concentrations. The sections were
then stained with Masson’s trichrome and examined under a conventional light microscope without
knowledge of the sample identity.
4.6.2 Tissue morphology and scoring of the samples
In the heart, the arteries and ventricular fibrous tissue formation were evaluated. Each sample was
scored from 0 to 3 (I, III) or from 0 to 4 (II, IV) according to the morphological changes.
Furthermore, in the kidneys, interstitial, tubular and glomerular changes were evaluated. The
samples were scored from 0 to 4 (II-IV) according to the morphological changes. Thereafter, the
damage score was calculated from the arithmetic mean of each group (n=4-10).
4.7 DETECTION OF mRNA FOR CTGF, COLLAGENS I AND III, AND TGF ββββ1
4.7.1 In situ hybridization
cDNA clones specific for human CTGF mRNA (1.1kb in pRc/CMV, provided kindly by G.
Grotendorst, University of Miami, USA) (Study I, II, IV), rat proα1 I collagen mRNA (α1 R2) and
proα1 III collagen mRNA (pRGR5) (Study I-II); rat TGFβ1 mRNA (Study II) were used for the
hybridization. The plasmids containing the inserted probe were linearized with restriction enzymes
to allow transcription of digoxigenin-labeled sense and antisense RNA probes according to the
Riboprobe Synthesis Kit method (Boehringer Mannheim, Mannheim, Germany). The paraffin
sections (5 µm) of the heart (Study I-IV), kidney (Study II) and pulmonary artery (Study II) were
placed onto Superfrost (Menzel-Gläser, Braunschweig, Germany) slides. The sections were
deparaffinized and hydrated through descending ethanol concentrations. Pretreatment included
incubation with 10 µg/ml proteinase K and 4 % paraformaldehyde post-fixation. The sections were
hybridized with labeled RNA-probe in the concentration of 1ng/µl at +50oC for 18 h. The slides
were washed under stringent conditions including treatment with RNAse A. Digoxigenin-labeled
probes were detected following the methods from the DIG-detection kit (Boehringer Mannheim,
antibody dilution 1:2000). After a 16-hour colour substrate incubation the slides were
counterstained with hematoxylin and coverslipped with aqueous-based mounting medium. Staining
was accepted positive when seen with the antisense probe only.
39
4.7.2 Northern blot
RNA extraction
Total RNA was extracted from the heart (Study I, II, IV) and kidney (Study II) by using the method
of Chomczynski and Sacchi (1987) and the RNA content was determined spectrophotometrically at
wavelengths 260 nm and 280 nm. Aliquots of the total RNA were size-separated by electrophoresis
on agarose gels. After the integrity and uniform loading of the gels were confirmed with ethium
bromide staining, the RNA was transferred from the gels to nylon membranes by blotting
(MagnaGraph Nylon Transfer Membrane; Micron Separations Inc., Westborough, MA, USA.
PosiBlot, Stratagene, La Jolla, CA, USA). The membranes were placed on filter papers, dried, UV-
crosslinked (Spectrolinker, Spectronics Corporation, Westbury, NY, USA) and stored at +4°C until
hybridization.
Labeling of the probe
The PCR amplified cDNA clones for human CTGF mRNA 1.1kb in pRc/CMV (Study I, II, IV), rat
proα1 I collagen mRNA (α1 R2) and rat proα1 III collagen mRNA (pRGR5) (Study I, II), rat TGFβ1
mRNA (Study II), and rat GAPDH mRNA (I, II, IV) as a reference probe were labeled with (32P)dCTP
by random priming (High Prime DNA labeling kit, Boehringer Mannheim). The unincorporated
label was separated with elution (NICK Column, Amersham Pharmacia Biotech AB, Uppsala,
Sweden).
Hybridization
The hybridization was performed at +42ºC for 18 h in hybridization solution (50% formamide, 1M
NaCl, 1% SDS, 5x Denhardt’s solution, 10% dextran sulphate and 100µg/ml herring sperm DNA).
The filters were washed three times with 0.1% SDS in 2x SSC at +22ºC and twice with 0.1% SDS
in 0.2 SSC at +55ºC. The bound probe was detected by autoradiography at -70ºC using Kodak X-
omat films (Eastman Kodak Company, NY, NY, USA). The films were developed and scanned.
The band intensities were measured with computer densitometry (Bio Image Intelligent Quantifier,
B. I. Systems Corp. Ann Arbor, MI, USA). The amount of the detected mRNA for CTGF, proα1 I
collagen, proα1 III collagen and TGFβ1 were calculated in relation to the expression of GAPDH
mRNA of the corresponding sample.
40
4.7.3 Reverse transcriptase-polymerase chain reaction (RT-PCR) assay for CTGF mRNA
The RNA was extracted from the whole hearts (II, III) and right ventricle (II) with Trizol reagent
(Gibco Life Technologies, Invitrogen Corporation, Paisley, UK), according to the instructions of the
manufacturer. After extraction, a 1 µg aliquot of the total RNA was treated with DNAase 1
(Deoxyribonuclease 1, Sigma Chemical Co., USA) and reverse-transcribed to cDNA by incubation
for 50 minutes at +45ºC in the presence of reverse transcriptase (Enhanced Avian HS RT-PCR kit,
Sigma Chemical Co., USA). 2 µl of cDNA was subjected to a quantitative real time polymerase
chain reaction (PCR) by Lightcycler Instrument (Roche Diagnostics, Neuilly sur Seine, France) for
the detection of the CTGF mRNA and GAPDH mRNA. The samples were amplified using
FastStart DNA Master SYBR Green 1 (Roche Diagnostics) in the presence of forward and reverse
primers (Sigma Genosys, London, UK). After amplification the quality of the PCR products was
analyzed and the quantities of the CTGF and GAPDH PCR products were quantified with an
external standard curve amplified from a purified PCR product.
4.8 IMMUNOHISTOCHEMISTRY
Cryosections (5 µm) were treated with acetone (10 min at -20°C), chloroform (30 min at room temp
(RT)) and air-dried. Primary antibodies (mouse anti-rat ED1 (Study II, III) ED2 (Study II), CD4
(Study II, III), CD8 (Study II, III) (Serotec Ltd, Oslo, Norway), anti-rat CTGF (for paraffin
sections) (Study II, IV) (Abcam, Cambridge, UK) and anti-mouse PCNA (Study II) (Stressgen
Biotechnologies Corp. Victoria, BC Canada), were applicated for 30 min at RT. The slides were
then treated with secondary antibody (peroxidase-conjugated rabbit anti-mouse immunoglobulins;
DAKO A/S, Glostrup, Denmark) for 30 min at RT. After treatment with the third antibody (HRP-
F(ab´)2 goat anti-rabbit (Zymed, SF, CA, USA) for 30 min at RT, the reaction was made visible by
an AEC (3-amino-9-ethyl carbazole) solution containing hydrogen peroxidase. Finally, the samples
were counterstained with hematoxyline and mounted. From the processed cardiac samples, the
amount of the CTGF positive label was scored from 0 to 4 by using a light microscope (IV). From
the renal samples, the whole cortical and medullary area was photographed and the relative amount
of primary antibody positive label per sample was determined with computerized densitometry
(Leica IM500 and Leica QWIN software; Leica Microsystems AG, Heerbrugg, Switzerland).
In situ detection of DNA fragmentation (Study II) was made by the TUNEL method according to
the procedures in Apoptosis Detection Kit (Apoptag Peroxidase in Situ Apoptosis Detection Kit,
Intergen Company, Oxford, UK). In brief, the cardiac and renal sections (5µm) were deparaffinized,
41
hydrated and treated with proteinase K. Endogenous peroxidase was quenched with 3% hydrogen
peroxide. Terminal deoxynucleotidyl transferase (TdT) enzyme was applied on the specimens and
incubated at +37°C for one hour. The sections were labeled with an anti-digoxigenin conjugate and
developed with a peroxidase substrate. Finally, the slides were counterstained with hematoxyline,
dehydrated and mounted. The degree of apoptosis was measured by counting the number of the
apoptotic cells (excluding the leukocytes) in 10 high-powered fields for each slide.
4.9 BIOCHEMICAL DETERMINATIONS
Urinary protein concentration (I) was measured by the Lowry method (Lowry et al., 1951).
Urinary albumin concentration (II-IV) was measured by ELISA, using rat albumin as a standard
(Celltrend GmbH, Luckenwalde, Germany).
Serum lactate dehydrogenase (s-LDH) activity (II) was determined by UV-kinetic analysis (Hitachi
912, United Laboratories, Helsinki, Finland).
Serum ionized magnesium [S-Mg2+] (IV) was measured with ion-selective electrode (NOVA CRT
8+ electrolyte analyzer (Nova Biomedical, Waltham, NJ, USA).
4.10 STATISTICAL ANALYSIS
Statistical analysis was carried out by one-way analysis of variance (ANOVA) supported by the
Tukey’s test (I) or Fisher’s Least-Significant-Difference test (LSD) (II-IV) for pairwise
comparisons. The two-way ANOVA for repeated measurements was applied for data consisting of
repeated observations. The correlation between the SBP and CTGF expression (I) was calculated
with Pearson’s correlation matrix followed by the two-tailed t-test. The level of statistical
significance was regarded as P<0.05. The results are expressed as mean ± S.E. mean. The data was
analyzed by using SYSTAT statistical software (SYSTAT Inc, Evanston, IL, USA).
4.11 ETHICS OF THE STUDY
The study-protocols were approved by the Animal Experimentation Committee of the Institute of
Biomedicine, University of Helsinki, Finland.
42
5 RESULTS
5.1 BRIEF SUMMARY OF THE MAIN RESULTS
Study I
The calcineurin inhibitor cyclosporine induced a marked hypertension, myocardial damage and
CTGF overexpression in the SHRs on high-sodium diet. The expression of the CTGF correlated
with blood pressure and was effectively prevented with an ACE inhibitor enalapril and an AT1
receptor antagonist valsartan.
Study II
Ang II induced marked inflammatory end organ damage and CTGF overexpression in the dTGRs.
Myocardial expression of the CTGF increased in a time- and blood pressure-dependent manner and
located in the myocardial structures affected by increased inflammatory response and pressure-load.
Treatment with an immunosuppressant cyclosporine and an AT1 receptor antagonist valsartan
protected against the Ang II-induced inflammatory response and CTGF overexpression thus
showing the importance of the Ang II and calcineurin signaling in the regulation of the CTGF gene.
Study III
Ang II induced severe inflammatory end organ damage, activation of the redox-sensitive
transcription factors (NF-κB, AP-1) and CTGF overexpression in the dTGRs. The Ang II-induced
infiltration of inflammatory cells, activation of inflammatory mediators NF-κB and AP-1 as well as
the overexpression of the CTGF was effectively prevented by suppression of the oxidative stress
with the antioxidant -lipoic acid.
Study IV
The Ang II-induced inflammatory end organ damage and CTGF overexpression in the dTGRs was
prevented with concomitant dietary magnesium supplementation. A calcineurin inhibitor tacrolimus
produced similar beneficial effects as cyclosporine in the Study II. Magnesium supplementation also
improved the therapeutic effects of the tacrolimus, which produced marked hypomagnesemia when
given as monotherapy.
43
5.2 BLOOD PRESSURE AND CARDIAC HYPERTROPHY
In the SHRs on high-sodium diet (I), CsA (5 mg/kg/d) produced a marked hypertensive effect
during the six-week treatment period. Concomitant enalapril and valsartan treatment antagonized
the hypertensive effect of the CsA. CsA tended to further promote LVH but the difference did not
reach statistical significance (P=0.098). Enalapril and valsartan protected against the development
of LVH.
During the three-week experimental periods, untreated dTGRs developed a marked hypertension
and cardiac hypertrophy compared to the age-matched normotensive SD rats (II-IV). Valsartan
treatment (II) normalized blood pressure and cardiac hypertrophy in the dTGRs. Calcineurin
inhibitors CsA (2 mg/kg/d) and tacrolimus (II, IV) produced a modest decrease in blood pressure
and cardiac hypertrophy. Dietary magnesium had a slight antihypertensive effect (IV) with a
decrease in the cardiac weight-to-body weight ratio. In contrast, combination treatment with
tacrolimus and magnesium (IV) normalized blood pressure and ameliorated cardiac hypertrophy.
Treatment with lipoic acid (III) had a mild antihypertensive effect without a significant reduction in
cardiac hypertrophy. Mammalian TOR inhibition by everolimus (II) had no effect on blood pressure
or cardiac hypertrophy in the dTGRs.
5.3 URINARY PROTEIN EXCRETION
Urinary protein (I) or albumin (II-IV) was measured as an index of the renal damage.
In the SHRs on high sodium diet, CsA caused a marked proteinuria which was 3.5-fold higher than
in the control group. In addition, CsA treatment resulted in an elevated level of serum creatinine and
a decline in a creatinine clearance. Antagonism of the RAS with enalapril or valsartan prevented the
increase in the urinary protein excretion. Nevertheless, despite the treatments, the urinary protein
excretion in the SHRs remained at a higher level than usually seen in their normotensive counter
parts, Wistar Kyoto rats.
The dTGRs developed a marked albuminuria, which was from 20 to 150-fold higher than in the SD
rats (II-IV). The AT1-receptor antagonist valsartan, as well as CsA, tacrolimus (alone or combined
with magnesium) and lipoic acid (II-IV) protected against the development of albuminuria
effectively, whereas everolimus (II) had a less marked effect. In contrast, magnesium treatment did
not have an effect on the urinary albumin excretion.
44
5.4 HISTOPATHOLOGY
5.4.1 Myocardial lesions
In the SHRs receiving high sodium diet (I), every ventricular sample had pathological alterations.
The majority of the epicardial and intramuscular arteries showed adventitial scarring, medial
thickening and smooth muscle cell vacuolization. The ventricular muscle had patches of thin
fibrotic scars and signs of recent infarcts. The lesions in the CsA (5 mg/kg/d) group were more
severe than in the control group. The epicardial and intramuscular arteries manifested marked
adventitial fibrosis, varying degrees of medial thickening and smooth muscle cell vacuolization.
Also the number and area of the observed myocardial scars exceeded those seen in the control
group. The cardiac damage index value did not differ significantly between the control and CsA
groups. In contrast, the cardiac damage index value was markedly lower with the higher dose of
valsartan when compared to the CsA group.
Treatment with the ACE inhibitor enalapril or the lower dose of the angiotensin AT1 receptor
antagonist valsartan prevented the development of the CsA-induced pathological alterations,
whereas the higher dose of valsartan seemed to be even more beneficial.
The hearts of the untreated dTGRs (II-IV) showed severe pathological alterations. The epicardial
and intramuscular arteries had perivascular inflammation, adventitial scarring, medial thickening
and sometimes fibrinoid necrosis. The intramuscular arteries showed marked medial/intimal
hyperplasia (concentric hypertrophy) leading to vessel occlusion. The ventricular muscle had
patches of fibrotic scars and signs of recent infarcts with inflammation. Cell proliferation as well as
apoptosis was increased in the hearts of the untreated dTGRs. Treatment with the AT1 receptor
antagonist valsartan (II) prevented the Ang II-induced morphological damage in the heart.
Calcineurin inhibition with CsA (2 mg/kg/d) (II) had no major effect on the cardiac morphology.
Although CsA protected against the Ang II-induced inflammation, cell proliferation, apoptosis and
myocardial infarcts, arteries were still notably affected. Interestingly, calcineurin inhibitor
tacrolimus (IV) had an evident cardioprotective effect. Lipoic acid (III) effectively prevented Ang
II-induced vascular lesions and myocardial infarcts. Treatment with magnesium alone (IV) had a
slight cardioprotective effect, whereas combination treatment with tacrolimus provided a very
45
effective inhibition against the Ang II-induced myocardial lesions. Interestingly, myocardial
damage tended to worsen by everolimus (II). Everolimus treatment caused numerous infarcts with a
marked accumulation of monocytes/macrophages. Intramuscular and epicardial arteries were
notably thickened and had areas of fibrinoid necrosis and perivascular inflammation.
5.4.2 Renal lesions
The description of the renal histopathology in the Study I has been previously published (Lassila et
al., 2000). In the SHRs on high sodium diet (I), there were minor pathological alterations involving
a small portion (4%) of the glomeruli. Neither tubular nor interstitial changes were detected. In
contrast, in the CsA group one-third of the glomeruli were apparently damaged. Within the affected
glomeruli, the pathological changes varied from a slight mesangial matrix expansion to a severe
necrosis and capillary collapse. Interstitial fibrosis of striped pattern was also found in the cortical
areas of the CsA-treated SHRs. Tubular atrophy and dilatation located in the tubuli surrounded by
fibrotic tissue. The large renal arteries in the CsA group were mostly normal, only a slight
thickening of the adventitia was found, whereas smaller arteries had medial changes ranging from a
minor smooth muscle cell vacuolization to a massive smooth muscle and endothelial cell
proliferation. All the CsA-induced pathological changes were completely prevented by blocking the
RAS with enalapril or valsartan (Lassila et al., 2000).
The kidneys of the untreated dTGRs (II-IV) had severe histopathological changes as indicated by
the increased renal damage index. The damage in the glomeruli ranged from a slight mesangial
expansion to a capillary collapse, glomerular sclerosis or necrosis. The intrarenal arteries had
varying degrees of medial/intimal hyperplasia and fibrinoid necrosis of the vessel wall. There was
marked perivascular and periglomerular inflammation characterized by an abundance of ED1, ED2,
CD4 and CD8 immunopositive cells. In addition, the redox-sensitive intracellular mediators of
inflammation, NF-κB and AP-1 were activated in the dTGRs (II). The tubules were affected to a
minor extent. Some tubuli were atrophied or dilated when surrounded by interstitial fibrotic tissue.
Part of the tubuli were necrotic or had peritubular fibrosis with inflammation. The Ang II-induced
cellular apoptosis located primarily in the epithelium of the proximal tubules. Valsartan, CsA,
tacrolimus and lipoic acid (II-IV) prevented the Ang II-induced renal damage efficiently, whereas
magnesium (IV) had lesser effect. The combination treatment with magnesium and tacrolimus
produced a very effective protection against the Ang II-induced renal damage. Although everolimus
partially prevented the development of albuminuria in the dTGRs (II), it still increased the amount
and severity of the renal damage in the dTGR. Lesions of the intrarenal arteries were similar but
46
more severe than in the dTGR group. Proximal tubules had necrosis and apoptosis. Patches of
interstitial fibrosis and ED1/ED2 positive inflammatory cells were seen throughout the sample.
However, everolimus partially attenuated the T cell-mediated inflammatory response, and cell
proliferation in the kidneys.
5.5 EXPRESSION OF CTGF
5.5.1 Myocardial expression of CTGF
In the SHRs (I), in situ hybridization showed a minor CTGF mRNA positive label in the epicardial
artery media where it was expressed by a small number of smooth muscle cells. There was a faint
CTGF expression in the ventricular fibrotic scars. CTGF mRNA expression was markedly
upregulated in the arterial media of the CsA group, where the positively labeled cells had the
phenotype of a smooth muscle. Equally to the control group, the CTGF positive label was detected
mostly in the vascular media, and in the extensive ventricular scars. Concomitant treatment with
enalapril and the lower dose of valsartan prevented the increment in CTGF mRNA expression,
whereas treatment with the higher dose of valsartan reduced CTGF expression by 75% compared to
the control group, and by 85% compared to the CsA-treated SHR on high sodium diet. When the
expression of the myocardial CTGF mRNA was compared between the 14-week-old hypertensive
SHR rats and the age-matched normotensive WKY rats on low-sodium diet, we noticed a strain-
specific induction of the CTGF mRNA in the SHRs.
In the untreated dTGRs (II-IV), as detected with in situ hybridization, immunohistochemistry and
Northern blot, CTGF mRNA and protein expression was markedly up-regulated especially in the
arterial media. A strong CTGF mRNA expression was also detected in the inflamed areas of the
vasculature and muscle. The fibrotic scars and infarcts of the ventricle had a strong CTGF mRNA
positive label in the outer boundaries (fresh infarct) or throughout the area (scar) of the lesion. In
the SD group, a faint CTGF mRNA expression was detected in the media of epicardial and
intramuscular arteries. In the ventricular muscle only a few positively labeled cells were noted.
Valsartan, CsA, tacrolimus, lipoic acid (0.047±0.018 vs. 0.2±0.049; P=0.002; n=6) and magnesium
(II-IV) prevented the Ang II-induced CTGF gene expression completely, whereas everolimus
treatment (II) had no effect on the CTGF expression.
47
5.5.2 Renal expression of CTGF
In the kidneys of the dTGRs (II), CTGF mRNA and peptide expression located mainly in the renal
corpuscles, arteries and in the interstitium. There was a marked up-regulation of the CTGF mRNA
expression in the media of the arcuate, interlobular and afferent arteries. Also, an enhanced
expression was detected in the interstitial and glomerular areas with inflammation, necrosis or
fibrosis. The SD group had a slight CTGF mRNA positive signal mainly in the same areas as in the
dTGR rats. However, there was no detectable signal in the tubules or interstitium, whereas a diffuse
signal was expressed in the vascular media. Treatment with valsartan and CsA protected effectively
against the Ang II-induced increase in CTGF mRNA. Treatment with everolimus (II) resulted in an
opposite effect. It further increased the expression of the renal CTGF mRNA.
5.5.3 Time- and blood pressure-dependent expression of CTGF
In the SHRs (I), we noticed a close correlation between the systolic blood pressure and myocardial
CTGF expression.
The expression of the myocardial CTGF mRNA was similar in the juvenile (3-4 week-old) dTGRs
and SD rats (II). Both in the heart and kidneys of the dTGRs, the temporal expression of the CTGF
mRNA revealed a strong up-regulation in the gene expression at the onset of hypertension between
the postnatal weeks 4 and 5.5. The difference in CTGF mRNA expression between the weeks 5.5
and 7 was less pronounced. At the age of 7 weeks, CTGF mRNA expression in the heart and
kidneys of the untreated dTGRs was 3.5 and 1.65 -fold higher as compared to the normotensive SD
rats, respectively.
To further elucidate the role of blood pressure as a regulator of the CTGF expression, also low-
pressure cardiovascular structures (right ventricle, pulmonary artery) were examined. The
expression of the CTGF mRNA in the right ventricle of the 7-week-old SD and dTGRs indicated a
noticeable but not significant increase in the amount of the CTGF mRNA in dTGR. In the
pulmonary arteries of the SD and dTGRs the CTGF mRNA positive signal was almost absent,
indicating no differences between these groups.
The main findings and effects of treatment with different compounds in corresponding animals are
summarized in Table 2.
Tab
le 2
. Mai
n fin
ding
s in
the
rats
and
effe
cts
of tr
eatm
ent w
ith d
iffer
ent c
ompo
unds
in c
orre
spon
ding
ani
mal
s (S
tudy
I−IV
).
Stu
dy
Str
ain
Tre
atm
ent
SB
P
Car
diac
hy
pert
roph
y M
yoca
rdia
l C
TG
F m
RN
A
I S
HR
I I I I S
HR
S
HR
S
HR
SH
R
HS
HS
+C
sA
HS
+C
sA+
Ena
30
HS
+C
sA+
Val
3
HS
+C
sA+
Val
30
−−
−
↑(↑
)
Car
diac
dam
age
− ↑↑ ↓
↓↓↓
↓↓
↓↓
↓↓
↓↓
↓ ↓↓
(↓)
↓ ↓↓
dT
GR
=
d
oub
le t
ran
sgen
ic r
at h
arb
orin
g hu
man
ren
in a
nd
angi
ote
nsi
no
gen
gen
es
SH
R
=
spo
nta
neo
usl
y h
yper
ten
sive
rat
CsA
=
cy
clo
spo
rine
(5m
g/kg
/d s
.c.
in S
tud
y I;
2m
g/kg
/d s
.c.
in S
tud
y II)
HS
=
h
igh
sod
ium
die
t (s
odiu
m 2
.6%
of t
he
cho
w d
ry w
eigh
t)
En
a 30
=
en
alap
ril 3
0m
g/kg
/d p
.o.
Val
3
=
vals
arta
n 3
mg/
kg/d
p.o
. V
al 3
0
=
vals
arta
n 3
0m
g/kg
/d p
.o.
Ren
al d
amag
e
− ↑↑
↓↓
↓↓
↓↓
Mg
=
Tac
ro
=
tacr
olim
us
1m
g/kg
/d s
.c.
-lip
oic
aci
d
=
-lip
oic
aci
d 3
50m
g/kg
/d p
.o.
SD
=
S
pra
gue
Daw
ley
rat
Eve
rolim
us
=
(SD
Z R
AD
) 2
.5m
g/kg
/d p
.o.
mag
nes
ium
(0
.6%
of t
he
cho
w d
ry w
eigh
t) a
aa
aa
bb
bb
b
bb
bb
b
bb
bb
b
SB
P
=
syst
olic
blo
od
pre
ssu
re
↑↑
II
dTG
R
Veh
icle
↓↓
↓↓
↓↓
↓↓
II S
D
Veh
icle
II
dTG
R
Val
30
↑↑
↑
↑
− c
ontr
ol; (
↑) s
light
ly in
crea
sed;
↑ in
cre
ased
; ↑↑
sub
stan
tially
incr
ease
d;
↔ n
o si
gnifi
cant
cha
nge
; (↓) s
light
ly d
ecr
eas
ed; ↓
decr
eas
ed; ↓
↓ s
ubst
antia
lly d
ecre
ased
; a
com
pare
d to
SH
R+
HS
(S
tud
y I)
; b
com
pare
d to
SH
R+
HS
+C
sA (
I); c co
mpa
red
to S
D
rats
(II-
IV);
d c
ompa
red
to u
ntre
ated
dT
GR
s (I
I-IV
).
II ↓
↓
↓
↓(↓
) dT
GR
C
sA
II ↓
↔↓
↑
↑dT
GR
E
vero
limus
III
↓
↓
↓↓
dTG
R
-Lip
oic
aci
d
IV
↓
↔
↓
dTG
R
Mg
IV
↓↓
↓
↓↓
dTG
R
Tac
ro
IV
↓↓
↓↓
↓↓
↓↓
dTG
R
Tac
ro+
Mg
−−
−−
−
↑↑
↑↑ ↓↓
↓
↓↓
(↑)
↓↓
↓↓
↓↓
↓↓
cc
cc
c
dd
dd
d
dd
dd
d
dd
dd
d
dd
dd
d
dd
dd
d
dd
dd
d
dd
dd
d
↓
48
6 DISCUSSION
The hypertension-induced end organ damage predisposes the hypertensive patients to numerous
cardiovascular complications leading to premature disability and mortality. The deterioration of the
cardiovascular and renal function results partly from the pathologic inflammatory reaction and
connective tissue accumulation occurring also by blood pressure-independent mechanisms.
Although the research has today focused to explore the role of locally acting growth factors and
mediators of connective tissue formation, the exact mechanisms contributing to the hypertension–
induced inflammatory end organ damage remain still more or less obscure.
This study investigated the role of the CTGF in the pathogenesis of hypertension-induced end organ
damage in two hypertensive animal models with increased RAS activity: CsA-treated SHRs on high
sodium diet and dTGRs. As regulators of the CTGF expression, the participation of the increased
blood pressure and Ang II were studied.
6.1 METHODOLOGICAL ASPECTS
6.1.1 Increased RAS activity in SHR and dTGR
The SHR is the most widely used animal model for human hypertension. The SHR is an inbred
strain which develops hypertension and its complications with increasing age. Although criticized
as being an inappropriate model for human hypertension, the arterial hypertension in the SHR and
essential human hypertension share many similarities in the pathogenic mechanisms (Trippodo and
Frohlich, 1981). To examine the pathogenesis of the CsA-induced hypertension and end organ
damage, we have developed an animal model for CsA toxicity, i.e. the CsA-treated SHR on high
sodium diet (Mervaala et al., 1997). This animal model expresses increased RAS activity and
develops hypertension and renal lesions similar to CsA-treated humans (Mervaala et al., 1997;
Lassila et al., 2000). Importantly, the development of hypertension and nephrotoxicity is achieved
by using an adequate drug dosage (CsA 5mg/kg/d) producing therapeutically high, but relevant
blood concentration (750 ng/ml) (Mervaala et al., 1997).
Previously, majority of the experimental studies focusing on the pathogenesis of CsA toxicity were
conducted in normotensive rats receiving either normal chow with sodium concentration
approximately 0.25-0.3 % w/w, or sodium-depleted diet (Burdmann et al., 1995; Shihab et al.,
1999). In these animal models a fairly high CsA dosage (usually 15 mg/kg/d producing
49
50
blood CsA concentrations of 5000-6000 ng/ml) causes renal damage similar to that found in the
CsA-treated patients (Shihab et al., 1999). However, even though CsA induces pronounced renal
damage in these animal models, the rats usually remain normotensive. Therefore these animal
models are not very suitable for studying the mechanisms of CsA-induced hypertension.
In experimental rat models CsA increases PRA regardless of the sodium content of the diet
(Burdmann et al., 1995; Mervaala et al., 1997). Although the administration of CsA in humans is
usually associated with volume-expanded, low renin form of hypertension, CsA has also been
reported to elevate PRA in cardiac and liver transplant patients and plasma Ang II levels in patients
with psoriasis (Julien et al., 1993; Edwards et al., 1994). Since the clinical CsA treatment in
humans is partly limited by the drug-induced hypertension and nephrotoxicity, and the CsA-induced
hypertension has been shown to depend on the level of dietary salt (Curtis et al., 1988; Textor et al.,
1994), we believe that our animal model provides valuable information when studying the CsA-
induced hypertension and its associated complications.
The dTGR was originally developed for studying human renin inhibitors which ordinarily do not
function in rats. The human components of RAS in the dTGR do not interact with the endogenous
rat RAS (Ganten et al., 1992; Bohlender et al., 1997). Hypertension, vascular inflammation and end
organ damage in the dTGR are due to increased Ang II synthesis by the human components of the
RAS. Ang II concentrations in the circulation and in the tissues are about 3 to 5-fold higher in the
dTGR compared to non-transgenic SD controls (Mervaala et al., 2000b). Therefore, the dTGR can
be considered as an appropriate model for studying the Ang II-induced pathologic effects on blood
pressure and end organ structure/function.
6.1.2 Blood pressure measurements
In the present study, blood pressure was measured indirectly by the tail-cuff method. When a study
design requires monitoring of a large number of animals, the non-invasive tail-cuff method is
commonly chosen. The advantage of this method is its relative simplicity and low cost compared to
e.g. the radiotelemetric method. Tail-cuff recording correlates well with direct blood pressure
recordings where intra-arterial catheters are used (Bunag and Butterfield, 1982). However, tail-cuff
recording may overestimate the real blood pressure levels possibly affected by ambient temperature,
restrainers, smells, noise, and the tail-cuff itself. To minimize the stress-inducing stimuli, the blood
pressure measurements in the present study were performed on pretrained rats by the same person
in a quiet and peaceful environment.
51
6.2 EFFECT OF BLOOD PRESSURE ON CTGF EXPRESSION
In the present study, we noticed a close correlation between the systolic blood pressure and
myocardial CTGF expression in the SHRs. The CsA-treatment (5 mg/kg/d) produced a malignant
hypertension with marked end organ damage without an inflammatory component. In addition to
elevated mechanical strain, the induction of the CTGF in CsA-treated SHRs could have also been a
consequence from other, yet unresolved events, like hypoxia or production of the ROS (Nishiyama
et al., 2003).
Next, the effect of blood pressure on the CTGF mRNA expression was examined more closely by
using the dTGRs. Although the expression of the myocardial CTGF mRNA was similar in 3-4
week-old SD and dTGR rats, a marked up-regulation of the myocardial and renal CTGF gene
expression in the dTGRs occurred between the postnatal weeks 4 and 5.5, and to a lesser extent
between the weeks 5.5 and 7. We noticed that the up-regulation of the CTGF gene occurred at the
onset of Ang II-induced hypertension before an overt myocardial and renal damage was observed.
For a further evaluation of the blood pressure-dependent expression of the CTGF, cardiac structures
not affected by the systolic blood pressure (right ventricle, pulmonary artery) were examined. The
CTGF mRNA level in the right ventricle of the 7-week old dTGRs was noticeably but not
significantly higher than in the SD rats.
Furthermore, when we examined the expression of the CTGF mRNA in the pulmonary arteries of
the dTGRs and SDs, there was no notable difference between these two rat strains. The CTGF
mRNA positive signal was almost completely absent from all the samples studied, which is in
contrast to the marked difference we have noted in the CTGF mRNA expression between the
myocardial arteries in the dTGR and SD.
Although it is difficult to separate the effects of hemodynamic and humoral factors in an in vivo
model, there are several reports which propose increased mechanical stress as an inducer of the
CTGF and connective tissue synthesis. In vitro studies have revealed that static and cyclic stress
enhances the expression of the CTGF (Riser et al., 2000; Hishikawa et al., 2001). The pathways by
which the induction of the CTGF is regulated in the conditions above remain obscure. The recently
discovered stretch-responsive element in the CTGF promoter region might be involved in the
regulation of the CTGF under mechanical stimuli. Previously, a mechanical strain-responsive
element has been found in the rat collagen I gene and the induction of collagen III gene has been
noted in association of cyclic mechanical stretch (Carver et al., 1991; Lindahl et al., 2002).
Furthermore, the studies by van Wamel et al. (2002) have shown that TGFβ1 mRNA expression in
stationary cardiomyocytes is increased by the release of Ang II from stretched cardiomyocytes.
52
6.3 EFFECT OF ANG II AND INFLAMMATORY RESPONSE ON CTGF EXPRESSION
Wound heals through inflammation and connective tissue formation. An exception can be seen in
the early phases of embryonic development when there is no inflammatory response to an injuring
stimulus. The healing occurs by the proliferation of the cells surrounding the lesion and no fibrosis
occurs. Interestingly, in the early embryonic stage CTGF participates in the organogenesis, and
even injected CTGF mRNA does not promote fibrosis, but instead it results in an abnormal
differentiation of embryonic structures (Abreu et al., 2002).
In several studies, the up-regulation of the CTGF expression has been noted in conjunction with
inflammatory lesions. Induction of the CTGF has been shown in the inflammatory diseases of
kidneys, lungs, liver, pancreas, skin, cardiovascular system, and colon (Table 1). Besides having an
inflammatory component, characteristic of these diseases is also an abnormal homeostasis of
connective tissue. The difficulty in auto-immune diseases is the prolonged state of inflammation
and activity of fibrosis-promoting growth factors, which does not seem to serve any physiological
function. This “inflammation-wound healing” occurs without previous traumatic episode and reacts
to the organisms own molecules as hostile invaders.
The participation of the RAS and Ang II in the processes of inflammation-connective tissue
formation has been clearly demonstrated. Besides acting as a circulating humoral system, RAS
operates also locally. The local RAS is particularly active in atherosclerotic arteries in which
increased expression of the ACE and AT1 receptor can be seen in the inflammatory cells of
atherosclerotic plaques (Fukuhara et al., 2000; Gross et al., 2002). In numerous experimental
studies, it has been noted that hindering the activity of RAS, either with ACE inhibitors or AT1
receptor antagonists, protects against the Ang II-induced NF-κB-mediated neointimal inflammation
in atherosclerosis, NF-κB-mediated inflammation of the renal cortex, inflammatory experimental
glomerulonephritis and diabetic nephropathy (Morrissey and Klahr, 1997; Hernandez-Presa et al.,
1998; Ruiz-Ortega et al., 1998; for review, see Schiffrin, 2002b).
Hypertension, vascular inflammation and end organ damage in the dTGR are due to increased Ang
II synthesis by the human components of the RAS (Mervaala et al., 2000b). In the dTGRs, marked
inflammatory cell recruitment, mainly consisting of monocytes and macrophages, as well as the up-
regulation of the adhesion molecules VCAM-1, ICAM-1, and the extracellular matrix component
fibronectin, are already present immediately after weaning (Mervaala et al., 1999; Müller et al.,
2000b). The interpretation made from these findings is that Ang II triggers inflammatory response
53
and exerts direct pro-inflammatory effects even by blood pressure-independent mechanisms related
to the activation of the redox-sensitive transcription factors NF-κB and AP-1, as well as oxidative
stress.
In the present study, we showed that in the dTGRs, the expression of the myocardial CTGF mRNA
was markedly up-regulated in the vascular media and in the inflamed and infarcted areas. Induction
of the renal CTGF mRNA was located mainly in the medial layer of the arteries, in the interstitium
and in the necrotic glomeruli. Both in the heart and kidneys, the expression of the CTGF co-located
very closely with infiltrated leukocytes suggesting an important role for inflammatory response in
the CTGF gene regulation. Furthermore, we noticed that the induction of the CTGF in the dTGRs
was associated with the concomitant activation of inflammatory mediators NF-κB and AP-1. In
contrast, in the CsA-treated (5 mg/kg/d) SHRs on high sodium diet, we did not notice any signs of
myocardial inflammation. Despite the lack of the visible inflammation in this model, there were
numerous scars in the myocardium indicating previous phases of reparative fibrosis and presence of
leukocytic cells. In addition, the contribution of the NF-κB and AP-1 in regulating the gene
expression of the CTGF in the CsA-treated SHR can be proposed on the basis of the recent findings
by Asai et al. (2003), who showed that chronic CsA-treatment in rats promotes the activity of the
AP-1 and NF-κB. The 50-fold increment in the observed plasma renin activity of the CsA group
compared to the group receiving vehicle, proposes the involvement of the RAS in regulating the
expression of the CTGF. It has been previously reported that CsA stimulates RAS and up-regulates
Ang II receptors in human vascular smooth muscle cells (Avdonin et al., 1999; for review, see
Lassila, 2002). Furthermore, high sodium diet has also been shown to promote cardiac ACE activity
in rats (Kreutz et al., 1995). The role of the RAS in regulating CTGF can be further proposed by the
presence of the NF-κB, AP-1 and TGFβ1 regulatory elements in the CTGF gene promoter region.
Besides stimulating the activity of the NF-κB and AP-1, Ang II induces fibrosis in the heart and
kidneys through TGFβ1 (Everett et al., 1994; Dostal, 2001). In the dTGRs, by using in situ
hybridization CTGF mRNA was noticed to co-locate very closely with TGFβ1 mRNA. This
suggests also the involment of the TGFβ1 as a regulator of the CTGF in this model. However, the
induction of the TGFβ1 occurred only in the kidneys of the dTGRs. Therefore, further studies would
be required to determine the role of the TGFβ1 as a regulator of the CTGF gene expression in this
model.
54
In the present study, the regulation of the CTGF expression seemed to involve the following Ang II
dependent pathways:
1. Ang II signaling through the AT1 receptor appeared to be involved as the expression of the CTGF
was markedly decreased by valsartan in the dTGRs and CsA-treated SHRs. In the SHRs, treatment
with valsartan resulted in a lower CTGF expression than could have been presumed from its
antihypertensive effect. This supports the findings by Candido et al. (2002) who demonstrated a
marked vascular CTGF overexpression and ACE activity in diabetic apolipoprotein-E knock-out
mice. ACE inhibitor therapy inhibited the development of atherosclerotic lesions and diabetes-
induced ACE and CTGF overexpressions in the aorta.
2. In the dTGRs, ROS seemed to be involved in the regulation of the CTGF gene, as the treatment
with antioxidant lipoic acid hindered the activity of the redox-sensitive NF-κB and AP-1, and
prevented the induction of the CTGF gene. Ang II stimulates NADPH oxidase to produce ROS,
which participate in the regulation of the VSMC growth, induction of vascular inflammatory
response, impairment of endothelial-dependent vascular relaxation, pathogenesis of cardiac
hypertrophy and stimulation of the CTGF expression (Griendling et al., 2000; Park et al., 2001).
3. In the present study, the Ang II-stimulated activation of the T cell calcineurin phosphatase
seemed to be involved in the Ang II-induced expression of the CTGF in dTGRs, as the blockade of
the calcineurin activity with CsA or tacrolimus protected against the inflammatory response and up-
regulation of the CTGF mRNA. Previously, it has been shown that human T cells synthesize CTGF
and Ang II promotes the proliferation and function of T cells via calcineurin dependent pathway
(Nataraj et al., 1999; Workalemahu et al., 2003). Nataraj et al. (1999) also found that calcineurin
inhibition completely blocked the ability of the Ang II to induce proliferation of the cultured splenic
lymphocytes, demonstrating that calcineurin is required for the stimulation of the lymphocyte
proliferation by AT1 receptors. Increased activity of the calcineurin has been connected to other
adverse events e.g. cardiac hypertrophy, heart failure, overexpression of the TGFβ1, activation of
the NF-κB, and organ transplant rejection (Molkentin et al., 1998; Molkentin and Dorn, 2001). In
our previous studies it was noted that, in dTGRs, Ang II induces inflammation even by blood
pressure-independent mechanisms and the inflammation with the subsequent end organ damage can
be prevented with calcineurin inhibition. (Mervaala et al., 2000a; Mervaala et al., 2000b).
55
4. The redox-sensitive mediators of inflammation, NF-κB and AP-1 probably mediated the final,
DNA-binding step in the CsA-treated SHRs and in the dTGRs. This could be proposed by the
presence of the NF-κB and AP-1-binding elements in the CTGF gene promoter region. To support
this speculation, a marked activation of the NF-κB and AP-1 was noticed in dTGRs. Treatment with
antioxidant lipoic acid resulted in a diminished activity of the NF-κB, AP-1, and suppression of the
CTGF gene expression. Furthermore, in the dTGRs, magnesium supplementation, which has been
shown to diminish the activation of the AP-1 and NF-κB, protected against the induction of the
CTGF gene (Asai et al., 2003). Although controversial data exist, NF-κB and AP-1 are today
considered as positive regulators of the CTGF expression (Blom et al., 2002).
6.4 POSSIBLE CLINICAL IMPLICATIONS
Currently, ACE inhibitors, AT1 receptor antagonists, and statins are widely used to prevent the
cardiovascular end organ damage in arterial hypertension. Besides having anti-hypertensive or
LDL-lowering effects, these drugs have been shown to diminish the accumulation of adverse
connective/scar tissue in the heart, kidney and vasculature. Despite the various beneficial effects of
the aforementioned drugs, the antifibrotic therapy could also be targeted on a single molecule.
Previous expectations focused on TGFβ1, which has a central role in connective tissue synthesis.
Unexpectedly, studies with anti-TGFβ1 antibody and TGFβ1-knockout mice have revealed the
importance of the TGFβ1 as a controller of growth and inflammation. In numerous experimental
studies, inhibition of the TGFβ1-signaling has resulted in hyperinflammation, atherosclerosis, and
malignancies (Murphy et al., 1999; Mallat et al., 2001; Engle et al., 2002). CTGF is induced by
various components of injuring conditions (high glucose, mechanical strain and inflammation) and
the presence of the CTGF in tissue samples and body fluids has been shown to correlate with the
degree of diabetic nephropathy and other fibrotic processes (Tamatani et al., 1998; Sato et al., 2001;
Riser et al., 2003). Whether CTGF mediates the immunomodulatory or anti-carcinogenic effects of
the TGFβ1 is not yet known. Acting as a downstream mediator of the TGFβ1-induced collagen
production, CTGF may provide a more selective drug target in anti-fibrotic therapy. The blockade
of the CTGF may thus avert the possible dangers associated with the antagonism of the TGFβ1.
On the basis of recent investigations CTGF has a potential of serving as a suitable drug target or an
early marker of various inflammatory/fibrotic disease states and a reliable indicator of response to
therapy.
56
7 SUMMARY AND CONCLUSIONS
This study investigated the expression of the CTGF in the pathogenesis of the hypertension-induced
end organ damage by using two hypertensive animal models with increased RAS activity: the CsA-
treated SHR on high sodium diet and the dTGR.
The main findings and conclusions are as follows:
• Arterial hypertension induced myocardial CTGF mRNA expression.
• In the dTGRs, Ang II induced CTGF expression in a time- and blood pressure-dependent
manner primarily via AT1 receptor stimulation. Ang II-induced CTGF overexpression was
linked to increased oxidative stress and inflammatory response of the vascular wall.
• Blockade of the RAS activity either with the ACE inhibitor or the AT1 receptor antagonist
prevented the overexpression of the CTGF gene.
• Calcineurin inhibitors CsA and tacrolimus as well as the antioxidant lipoic acid effectively
protected against the induction of the CTGF gene in the dTGR.
• Magnesium supplementation reduced the Ang II-induced myocardial damage and CTGF
overexpression. Additive therapeutic effects were found withmagnesium supplementation
andcalcineurin inhibitor.
57
ACKNOWLEDGEMENTS
This study was carried out at the Institute of Biomedicine, Pharmacology, of the University of
Helsinki during 1999-2003.
First, I wish to express my warm gratitude to my supervisor, Docent Eero Mervaala. His humoristic
and “workaholic” attitude kept me busy during these years. Working with him gave me loads of
knowledge, research funds ;-) and hopefully, some professional attitude in the field of
cardiovascular research.
My warm thanks also to my other supervisor, Professor Leena Lindgren, whose benevolently fierce
character is matched only by her professional skills.
I owe my respectful thanks to Professor Heikki Vapaatalo, the former head of the Department of
Pharmacology. He is a professor of the “good-old times” whose ideas and knowledge are of the
highest value.
My heartfelt thanks go to late Professor Juhani Ahonen, the father of this study. The kindness,
friendship and ideas of this “fly-fisherman” were unique. I would like to dedicate this work to him.
Professor Eero Saksela and Docent Ilkka Pörsti, the reviewers appointed by the Medical Faculty of
the University of Helsinki, are gratefully acknowledged for their valuable criticism and comments.
I would also like to thank Professors Esa Korpi, Heikki Karppanen, Ilari Paakkari and Ismo
Virtanen for the various valuable conversations we have had during these years.
I would like to express my sincere gratitude to Professor Krister Höckerstedt for providing the
laboratory at the Surgical Hospital at my disposal.
I am grateful to Docent Marja-Leena Nurminen, who kindly welcomed me in the cardiovascular
research group. She gave me (in her own peculiar way) the principles of the cardiovascular
pharmacology and research work. Our group had pleasant evenings with good wine and food
provided by Marja-Leena, and her husband Manu.
58
Respectful acknowledgements go to Marika Collin, whose coordination skills in various
assessments provided the needed feasible experimental methods. I am still laughing when I am
thinking our “smartass”-theories about everything.
I am grateful to my friend Markus Lassila, for his cheerful attitude in everyday life. Our research
work shared many topics which was beneficial for both of us. Thanks also go to Riikka Nevala and
Timo Vaskonen. We shared many delightful moments in the work and leisure time.
Cheerful gratitude goes to Saara Merasto and Marjut Louhelainen who provided the much needed
assistance during this research work. Their companionship and attitude gave me many laughs (and gray
hair).
I would also like to thank my friends and colleagues Kaija Inkinen, Docent Riitta Korpela, Docent
Irmeli Lautenschlager, Docent Ilkka Tikkanen, Docent Pekka Rauhala, Zhong Jian Cheng, Antti
Ohvanainen, Juha Ketonen, Anna-Stina Lax, Ilkka Reenilä, Petri “Pirtu” Vainio, Anna-Kaisa Pere,
Antti Väänänen, Teemu Helkamaa, Timi Martelius, Anneli von Behr, Toini Siiskonen, Sari
Laakkonen, Tarja Markov, Stephen Venn, Jesus Santisteban, Erkka Solatunturi, Eeva Harju,
Kristiina Haasio, Tuula Lähteenmäki and others.
I was fortunate to work with highly-skilled collaborators. My sincere thanks go to Professors
Friedrich Luft and Detlev Ganten; Docents Dominik Müller, Leena Krogerus and Risto Lapatto.
I would like to thank the following people: R.H. Böeckel, Andrew Hilary, Brendan Mulachy, Harri
Mauriainen, Henri Pulla, Marusha, Raymond Bourque and others for the various activities,
happenings and leisure time.
I am grateful to my relatives for their mental, professional (and financial) support and company I
received during these years.
My warmest thanks to my chequered, 18-year-old, four-footed, always demanding friend, Enni.
Thanks to Matilda “Mato Matala”, for keeping me up on my toes (and giving me more gray hair).
59
Finally, I owe my special gratitude to my very special soul mate Maija for giving me the necessary
kicks in everyday life. Without her, I think my greatest accomplishments would have been in the
areas of barbecue or kitty-litter-cleaning business.
This work was financially supported by the Academy of Finland, the Sigrid Jusélius Foundation,
the Kidney Foundation, the Research and Science Foundation of Farmos, and the Aarne Koskelo
Foundation.
Helsinki, October 2003
Piet Finckenberg
# 9
60
REFERENCES
Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A. Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem 2000, 275:15220-15225
Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002, 4:599-604
Aggarwal A, Esler MD, Lambert GW, Hastings J, Johnston L, Kaye DM. Norepinephrine turnover is increased in suprabulbar subcortical brain regions and is related to whole-body sympathetic activity in human heart failure. Circulation 2002, 105:1031-1033
Aikawa R, Nitta-Komatsubara Y, Kudoh S, Takano H, Nagai T, Yazaki Y, Nagai R, Komuro I. Reactive oxygen species induce cardiomyocyte apoptosis partly through TNF-alpha. Cytokine 2002, 18:179-183
Aikawa R, Nagai T, Tanaka M, Zou Y, Ishihara T, Takano H, Hasegawa H, Akazawa H, Mizukami M, Nagai R, Komuro I. Reactive oxygen species in mechanical stress-induced cardiac hypertrophy. Biochem Biophys Res Commun 2001, 289:901-907
Allen JT, Knight RA, Bloor CA, Spiteri MA. Enhanced insulin-like growth factor binding protein-related protein 2 (Connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1999, 21:693-700
Asai T, Nakatani T, Tamada S, Kuwabara N, Yamanaka S, Tashiro K, Nakao T, Komiya T, Okamura M, Kim S, Iwao H, Miura K. Activation of transcription factors AP-1 and NF-κB in chronic cyclosporine A nephrotoxicity: role in beneficial effects of magnesium supplementation. Transplantation. 2003, 75:1040-1044
Avdonin PV, Cottet-Maire F, Afanasjeva GV, Loktionova SA, Lhote P, Ruegg UT. Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int 1999, 55:2407-2414
Babic AM, Chen CC, Lau LF. Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol 1999, 19:2958-2966
Bader M, Peters J, Baltatu O, Muller DN, Luft FC, Ganten D. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med 2001, 79:76-102
Berk BC, Corson MA. Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ Res 1997, 80:607-616
Blalock TD, Duncan MR, Varela JC, Goldstein MH, Tuli SS, Grotendorst GR, Schultz GS. Connective tissue growth factor expression and action in human corneal fibroblast cultures and rat corneas after photorefractive keratectomy. Invest Ophthalmol Vis Sci 2003, 44:1879-1887
61
Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol 2002, 21:473-482
Bohle A, Ratschek M. The compensated and the decompensated form of benign nephrosclerosis. Pathol Res Pract 1982, 174:357-367
Bohlender J, Fukamizu A, Lippoldt A, Nomura T, Dietz R, Ménard J, Murakami K, Luft FC, Ganten D: High human renin hypertension in transgenic rats. Hypertension 1997, 29:428-434
Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994, 331:1286-1292
Bradham DM, Igarashi A, Potter RL, Grotendorst GR. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 1991, 114:1285-1294
Brigstock DR. The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr Rev 1999, 20:189-206
Bunag RD, Butterfield J. Tail-cuff blood pressure measurement without external preheating in awake rats. Hypertension 1982, 4:898-903
Burdmann EA, Andoh TF, Nast CC, Evan A, Connors BA, Coffman TM, Lindsley J, Bennett WM. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995, 269:491-489
Burgess JK, Johnson PR, Ge Q, Au WW, Poniris MH, McParland BE, King G, Roth M, Black JL. Expression of connective tissue growth factor in asthmatic airway smooth muscle cells. Am J Respir Crit Care Med 2003, 167:71-77
Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, Twigg SM, Dilley RJ, Cooper ME, Allen TJ. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002, 106:246-253
Carreau JP. Biosynthesis of lipoic acid via unsaturated fatty acids. Methods Enzymol 1979, 62:152-158
Carver W, Nagpal ML, Nachtigal M, Borg TK, Terracio L. Collagen expression in mechanically stimulated cardiac fibroblasts. Circ Res 1991, 69:116-122
Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH. CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol 2000, 32:1805-1819
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572
62
Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159
Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med 1988, 85:134-138
Dahl LK, Heine M. Primary role of renal homografts in setting chronic blood pressure levels in rats. Circ Res 1975, 36:692-696
Dammeier J, Brauchle M, Falk W, Grotendorst GR, Werner S. Connective tissue growth factor: a novel regulator of mucosal repair and fibrosis in inflammatory bowel disease? Int J Biochem Cell Biol 1998, 30:909-922
DiBona GF. Neural control of the kidney: functionally specific renal sympathetic nerve fibers. Am J Physiol Regul Integr Comp Physiol 2000, 279:1517-1524
di Mola FF, Friess H, Martignoni ME, Di Sebastiano P, Zimmermann A, Innocenti P, Graber H, Gold LI, Korc M, Buchler MW. Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis. Ann Surg 1999, 230:63-71
Dickinson CJ. Strokes and their relationship to hypertension. Curr Opin Nephrol Hypertens 2003, 12:91-96
Dostal DE. Regulation of cardiac collagen: angiotensin and cross-talk with local growth factors. Hypertension 2001, 37:841-844
Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X, Grotendorst GR. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J 1999, 13:1774-1786
Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens Suppl 1993, 11:13-18
Eberlein M, Heusinger-Ribeiro J, Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001, 133:1172-1180
Edwards BD, Chalmers RJ, O'Driscoll JB, Mitchell DM, Smith RJ, Lawson RS, Testa HJ, Ballardie FW. Angiotensin II as a risk factor for cyclosporin nephrotoxicity in patients with psoriasis. Clin Nephrol 1994, 41:350-356
Engle SJ, Ormsby I, Pawlowski S, Boivin GP, Croft J, Balish E, Doetschman T. Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. Cancer Res 2002, 62:6362-6366
Escobar E. Hypertension and coronary heart disease. J Hum Hypertens 2002, 16:61-63.
Esler M, Lambert G, Jennings G. Regional norepinephrine turnover in human hypertension. Clin Exp Hypertens A 1989, 11:75-89
63
Esler M, Rumantir M, Kaye D, Jennings G, Hastings J, Socratous F, Lambert G. Sympathetic nerve biology in essential hypertension. Clin Exp Pharmacol Physiol 2001, 28:986-989
Evans JL, Heymann CJ, Goldfine ID, Gavin LA. Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid. Endocr Pract 2002, 8:29-35
Everett AD, Tufro-McReddie A, Fisher A, Gomez RA. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. Hypertension 1994, 23:587-592
Franklin TJ. Therapeutic approaches to organ fibrosis. Int J Biochem Cell Biol 1997, 29:79-89
Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996, 107:404-411
Frazier KS, Grotendorst GR. Expression of connective tissue growth factor mRNA in the fibrous stroma of mammary tumors. Int J Biochem Cell Biol. 1997, 29:153-161.
Fu M, Xu S, Zhang J, Pang Y, Liu N, Su J, Tang C. Involvement of calcineurin in angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibroblast hyperplasia of rats. Heart Vessels 1999, 14:283-288
Fukuhara M, Geary RL, Diz DI, Gallagher PE, Wilson JA, Glazier SS, Dean RH, Ferrario CM. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension 2000, 35:353-359
Funck RC, Wilke A, Rupp H, Brilla CG. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol 1997, 432:35-44
Ganten D, Wagner J, Zeh K, Bader M, Michel JP, Paul M, Zimmermann F, Ruf P, Hilgenfeldt U, Ganten U, Kaling M, Bachmann S, Fukamizu A, Mullins JJ, Murakami K. Species specificity of renin kinetics in transgenic rats harboring human renin and angiotensinogen genes. Proc Natl Acad Sci USA 1992, 89:7806-7810
Gerth WC, Remuzzi G, Viberti G, Hannedouche T, Martinez-Castelao A, Shahinfar S, Carides GW, Brenner B. Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union. Kidney Int 2002, 62 Suppl 82:68-72
Giasson E, Meloche S. Role of p70 S6 protein kinase in angiotensin II-induced protein synthesis in vascular smooth muscle cells. J Biol Chem 1995, 270:5225-5231
Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992, 90:456-461
Govinden R, Bhoola KD. Genealogy, expression, and cellular function of transforming growth factor-beta. Pharmacol Ther 2003, 98:257-265
64
Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995, 25:1345-1350
Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000, 86:494-501
Gross CM, Gerbaulet S, Quensel C, Kramer J, Mittelmeier HO, Luft FC, Dietz R. Angiotensin II type 1 receptor expression in human coronary arteries with variable degrees of atherosclerosis. Basic Res Cardiol 2002, 97:327-333.
Grotendorst GR, Okochi H, Hayashi N. A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ 1996, 7:469-480
Gupta S, Clarkson MR, Duggan J, Brady HR. Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 2000, 58:1389-1399
Guron G, Friberg P. An intact renin-angiotensin system is a prerequisite for normal renal development. J Hypertens 2000, 18:123-137
Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr, Norman RA Jr. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 1972, 52:584-594
Hernandez-Presa MA, Bustos C, Ortego M, Tunon J, Ortega L, Egido J. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol 1998, 153:1825-1837
Heusinger-Ribeiro J, Eberlein M, Wahab NA, Goppelt-Struebe M. Expression of connective tissue growth factor in human renal fibroblasts: regulatory roles of RhoA and cAMP. J Am Soc Nephrol 2001, 12:1853-1861
Hirsch AT, Pinto YM, Schunkert H, Dzau VJ. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am J Cardiol 1990, 66:22D-30D
Hishikawa K, Nakaki T, Fujii T. Transforming growth factor-beta(1) induces apoptosis via connective tissue growth factor in human aortic smooth muscle cells. Eur J Pharmacol 1999, 385:287-290
Hishikawa K, Oemar BS, Nakaki T. Static pressure regulates connective tissue growth factor expression in human mesangial cells. J Biol Chem 2001, 276:16797-16803
Hood KA. Drug-induced gingival hyperplasia in transplant recipients. Prog Transplant 2002, 12:17-21
Howell DC, Goldsack NR, Marshall RP, McAnulty RJ, Starke R, Purdy G, Laurent GJ, Chambers RC. Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol 2001, 159:1383-1395
65
Hu ZW, Shi XY, Lin RZ, Chen J, Hoffman BB. Alpha1-Adrenergic receptor stimulation of mitogenesis in human vascular smooth muscle cells: role of tyrosine protein kinases and calcium in activation of mitogen-activated protein kinase. J Pharmacol Exp Ther 1999, 290:28-37
Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Fujimoto M, Grotendorst GR, Takehara K. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 1996, 106:729-733.
Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 2002, 14:681-685
Inkinen K, Soots A, Krogerus L, Lindroos P, Bruggeman C, Ahonen J, Lautenschlager I. Cytomegalovirus infection enhances connective tissue growth factor mRNA expression in a rat model of chronic renal allograft rejection. Transplant Proc 2001, 33:379
Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, Goldschmeding R. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 1998, 53:853-861
Ivkovic S, Yoon BS, Popoff SN, Safadi FF, Libuda DE, Stephenson RC, Daluiski A, Lyons KM. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 2003, 130:2779-2791
Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002, 45:173-202
Julien J, Farge D, Kreft-Jais C, Guyene TT, Plouin PF, Houssin D, Carpentier A, Corvol P. Cyclosporine-induced stimulation of the renin-angiotensin system after liver and heart transplantation. Transplantation 1993, 56:885-891
Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994, 93:2431-2437
Kaiura TL, Itoh H, Kubaska SM 3rd, McCaffrey TA, Liu B, Kent KC. The effect of growth factors, cytokines, and extracellular matrix proteins on fibronectin production in human vascular smooth muscle cells. J Vasc Surg 2000, 31:577-584
Kannel WB, Levy D, Cupples LA. Left ventricular hypertrophy and risk of cardiac failure: insights from the Framingham Study. J Cardiovasc Pharmacol 1987, 10:135-140
Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R; RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003, 63:1499-1507
Keller G, Zimmer G, Mall G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N Engl J Med 2003, 348:101-108
66
Kocak G, Aktan F, Canbolat O, Ozogul C, Elbeg S, Yildizoglu-Ari N, Karasu C. Alpha-lipoic acid treatment ameliorates metabolic parameters, blood pressure, vascular reactivity and morphology of vessels already damaged by streptozotocin-diabetes. Diabetes Nutr Metab 2000, 13:308-318
Koller A, Huang A. Impaired nitric oxide-mediated flow-induced dilation in arterioles of spontaneously hypertensive rats. Circ Res 1994, 74:416-421
Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991, 114:345-352
Kreutz R, Fernandez-Alfonso MS, Liu Y, Ganten D, Paul M. Induction of cardiac angiotensin I-converting enzyme with dietary NaCl-loading in genetically hypertensive and normotensive rats. J Mol Med 1995, 73:243-248
Kubo M, Kikuchi K, Nashiro K, Kakinuma T, Hayashi N, Nanko H, Tamaki K. Expression of fibrogenic cytokines in desmoplastic malignant melanoma. Br J Dermatol 1998, 139:192-197.
Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, Hack CE. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999, 100:96-102.
Lassila M, Finckenberg P, Pere AK, Krogerus L, Ahonen J, Vapaatalo H, Nurminen ML. Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. Br J Pharmacol 2000, 130:1339-1347
Lassila M. Interaction of cyclosporine A and the renin-angiotensin system; new perspectives. Curr Drug Metab 2002, 3:61-71
Leask A, Holmes A, Black CM, Abraham DJ. Connective Tissue Growth Factor Gene Regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem 2003, 278:13008-13015
Lehman JA, Calvo V, Gomez-Cambronero J. Mechanism of ribosomal p70S6 kinase activation by GM-CSF in neutrophils: Cooperation of a MEK-related, T421/S424-kinase and a rapamycin-sensitive, mTOR-related, T389-kinase. J Biol Chem 2003, 278:28130-28138
Levonen AL, Lapatto R, Saksela M, Raivio KO. Expression of gamma-glutamylcysteine synthetase during development. Pediatr Res 2000, 47:266-270,
Lindahl GE, Chambers RC, Papakrivopoulou J, Dawson SJ, Jacobsen MC, Bishop JE, Laurent GJ. Activation of fibroblast procollagen alpha 1(I) transcription by mechanical strain is transforming growth factor-beta-dependent and involves increased binding of CCAAT-binding factor (CBF/NF-Y) at the proximal promoter J Biol Chem 2002, 277:6153-6161
Liu J, Albers MW, Wandless TJ, Luan S, Alberg DG, Belshaw PJ, Cohen P, MacKintosh C, Klee CB, Schreiber SL. Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry 1992, 31:3896-3901
67
Liu J, Yang F, Yang XP, Jankowski M, Pagano PJ. NAD(P)H Oxidase Mediates Angiotensin II-Induced Vascular Macrophage Infiltration and Medial Hypertrophy. Arterioscler Thromb Vasc Biol 2003, 23:776-782
Lowry OH, Rosenbrough NJ, Farr Al, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951, 193:265-275
Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamate C, Merval R, Fradelizi D, Tedgui A. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001, 89:930-934
Manohar P, Pina IL. Therapeutic role of angiotensin II receptor blockers in the treatment of heart failure. Mayo Clin Proc 2003, 78:334-338
Margreiter R; European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002, 359:741-746
Martinerie C, Viegas-Pequignot E, Guenard I, Dutrillaux B, Nguyen VC, Bernheim A, Perbal B. Physical mapping of human loci homologous to the chicken nov proto-oncogene. Oncogene 1992, 7:2529-2534
Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol 1990, 6:597-641
McCormick SM, Eskin SG, McIntire LV, Teng CL, Lu CM, Russell CG, Chittur KK. DNA microarray reveals changes in gene expression of shear stressed human umbilical vein endothelial cells. Proc Natl Acad Sci USA 2001, 98:8955-8960
Merion RM, White DJ, Thiru S, Evans DB, Calne RY. Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med 1984, 310:148-154
Mervaala EM, Muller DN, Park JK, Schmidt F, Lohn M, Breu V, Dragun D, Ganten D, Haller H, Luft FC. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999, 33: 389-395
Mervaala EM, Pere AK, Lindgren L, Laakso J, Teravainen TL, Karjala K, Vapaatalo H, Ahonen J, Karppanen H. Effects of dietary sodium and magnesium on cyclosporin A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats. Hypertension 1997, 29:822-827
Mervaala EMA, Müller DN, Park JK, Dechend R, Schmidt F, Fiebeler A, Bieringer M, Breu V, Ganten D, Haller H, Luft FC. Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes. Hypertension 2000a, 35:360-366
Mervaala E, Muller DN, Schmidt F, Park JK, Gross V, Bader M, Breu V, Ganten D, Haller H, Luft FC. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension. 2000b, 35:587-594
Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001, 38:635-638
68
Miyagawa K, Dohi Y, Kojima M, Sato K. Magnesium removal impairs the regulatory role of rat endothelium. Hypertens Res 2000, 23:669-675
Moini H, Packer L, Saris NE. Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid. Toxicol Appl Pharmacol 2002, 182:84-90
Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228
Molkentin JD, Dorn II GW 2nd. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 2001, 63:391-426
Morales JM, Andres A, Rengel M, Rodicio JL. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001, 16:121-124
Morrissey JJ, Klahr S. Enalapril decreases nuclear factor kappa B activation in the kidney with ureteral obstruction. Kidney Int 1997, 52:926-933
Moussad EE, Brigstock DR. Connective tissue growth factor: what's in a name? Mol Genet Metab 2000, 71:276-292
Murphy M, Godson C, Cannon S, Kato S, Mackenzie HS, Martin F, Brady HR. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 1999, 274:5830-5834
Müller DN, Dechend R, Mervaala EMA, Park J-K, Schmidt F, Fiebeler A, Theuer J, Breu V, Ganten D, Haller H, Luft FC. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000a, 35:193-201
Müller DN, Mervaala EM, Dechend R, Fiebeler A, Park JK, Schmidt F, Theuer J, Breu V, Mackman N, Luther T, Schneider W, Gulba D, Ganten D, Haller H, Luft FC. Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. Am J Pathol 2000b, 157:111-122
Müller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Hampich F, Fiebeler A, Ju X, Finckenberg P, Theuer J, Viedt C, Kreuzer J, Heidecke H, Haller H, Zenke M, Luft FC.Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 2002, 161:1679-1693
Nakahara K, Nishimura H, Kuro-o M, Takewaki S, Iwase M, Ohkubo A, Yazaki Y, Nagai R. Identification of three types of PDGF-A chain gene transcripts in rabbit vascular smooth muscle and their regulated expression during development and by angiotensin II. Biochem Biophys Res Commun 1992, 184:811-818
Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995, 92:10663-10667
69
Nashan B. The role of Certican (everolimus, rad) in the many pathways of chronic rejection. Transplant Proc 2001, 33:3215-3220
Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit 2002a, 24:53-58
Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002b, 11:1845-1857
Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS, Ruiz P, Smithies O, Coffman TM. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 1999, 104:1693-1701
National Public Health Institute. The 1997 dietary survey of Finnish adults [Finnish]. Publications of the National Public Health Institute 1998, B8/1998
Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD. Paracrine regulation of the renal microcirculation. Physiol Rev 1996, 76:425-536
Nishiyama A, Kobori H, Fukui T, Zhang GX, Yao L, Rahman M, Hitomi H, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y. Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension. Hypertension 2003, 42:754-760
Oemar BS, Werner A, Garnier JM, Do DD, Godoy N, Nauck M, Marz W, Rupp J, Pech M, Luscher TF. Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation 1997, 95:831-839
O'Callaghan CJ, Williams B. The regulation of human vascular smooth muscle extracellular matrix protein production by alpha- and beta-adrenoceptor stimulation. J Hypertens 2002 20:287-294
Ohnishi H, Oka T, Kusachi S, Nakanishi T, Takeda K, Nakahama M, Doi M, Murakami T, Ninomiya Y, Takigawa M, Tsuji T. Increased expression of connective tissue growth factor in the infarct zone of experimentally induced myocardial infarction in rats. J Mol Cell Cardiol 1998, 30:2411-2422
Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J 1963, 27:282-293
Packer L, Witt EC, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Rad Biol Med 1995, 19:227-250
Pan LH, Beppu T, Kurose A, Yamauchi K, Sugawara A, Suzuki M, Ogawa A, Sawai T. Neoplastic cells and proliferating endothelial cells express connective tissue growth factor (CTGF) in glioblastoma. Neurol Res 2002, 24:677-683.
Paradis V, Dargere D, Vidaud M, De Gouville AC, Huet S, Martinez V, Gauthier JM, Ba N, Sobesky R, Ratziu V, Bedossa P. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999, 30:968-976
70
Park SK, Kim J, Seomun Y, Choi J, Kim DH, Han IO, Lee EH, Chung SK, Joo CK. Hydrogen peroxide is a novel inducer of connective tissue growth factor. Biochem Biophys Res Commun 2001, 284:966-971
Pereira RC, Durant D, Canalis E. Transcriptional regulation of connective tissue growth factor by cortisol in osteoblasts. Am J Physiol Endocrinol Metab 2000, 279:570-576
Ratajska A, Campbell SE, Sun Y, Weber KT. Angiotensin II associated cardiac myocyte necrosis: role of adrenal catecholamines. Cardiovasc Res 1994, 28:684-690
Ricupero DA, Rishikof DC, Kuang PP, Poliks CF, Goldstein RH. Regulation of connective tissue growth factor expression by prostaglandin E(2). Am J Physiol 1999, 277:1165-1171
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979
Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000, 11:25-38
Riser BL, Cortes P, DeNichilo M, Deshmukh PV, Chahal PS, Mohammed AK, Yee J, Kahkonen D. Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report. Kidney Int 2003, 64:451-458
Romero JC, Reckelhoff JF. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999, 34:943-949
Ruilope LM, Lahera V, Rodicio JL, Carlos Romero J. Are renal hemodynamics a key factor in the development and maintenance of arterial hypertension in humans? Hypertension 1994, 23:3-9
Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, Lorenzo O, Plaza JJ, Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 1998, 161:430-439.
Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, Plaza JJ, Egido J. Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension 2001, 38:1382-1387
Sadoshima J, Jahn L, Takahashi T, Kulik TJ, Izumo S. Molecular characterization of the stretch-induced adaptation of cultured cardiac cells. An in vitro model of load-induced cardiac hypertrophy. J Biol Chem 1992, 267:10551-10560
Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001, 27:140-146
71
Schiffrin EL; Canadian Institutes of Health Research Multidisciplinary Research Group on Hypertension. Beyond blood pressure: the endothelium and atherosclerosis progression. Am J Hypertens 2002a, 15:115-122.
Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002b, 113:409-418
Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003, 108:560-565
Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000, 103:253-262
Schober JM, Chen N, Grzeszkiewicz TM, Jovanovic I, Emeson EE, Ugarova TP, Ye RD, Lau LF, Lam SC. Identification of integrin alpha(M)beta(2) as an adhesion receptor on peripheral blood monocytes for Cyr61 (CCN1) and connective tissue growth factor (CCN2): immediate-early gene products expressed in atherosclerotic lesions. Blood 2002, 99:4457-4465
Schwab JM, Postler E, Nguyen TD, Mittelbronn M, Meyermann R, Schluesener HJ. Connective tissue growth factor is expressed by a subset of reactive astrocytes in human cerebral infarction. Neuropathol Appl Neurobiol 2000, 26:434-440
Segarini PR, Nesbitt JE, Li D, Hays LG, Yates JR 3rd, Carmichael DF. The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor is a receptor for connective tissue growth factor. J Biol Chem 2001, 276:40659-40667
van Setten GB, Blalock TD, Grotendorst G, Schultz GS. Detection of connective tissue growth factor (CTGF) in human tear fluid: preliminary results. Acta Ophthalmol Scand 2003, 81:51-53
Shakunaga T, Ozaki T, Ohara N, Asaumi K, Doi T, Nishida K, Kawai A, Nakanishi T, Takigawa M, Inoue H. Expression of connective tissue growth factor in cartilaginous tumors. Cancer 2000, 89:1466-1473
Shepherd JT. Increased systemic vascular resistance and primary hypertension: the expanding complexity. J Hypertens 1990, 8:15–27
Shihab FS, Andoh TF, Tanner AM, Yi H, Bennett WM. Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis. Kidney Int 1999, 56:2147-2159
Silver MA, Pick R, Brilla CG, Jalil JE, Janicki JS, Weber KT. Reactive and reparative fibrillar collagen remodelling in the hypertrophied rat left ventricle: two experimental models of myocardial fibrosis. Cardiovasc Res 1990, 24:741-747
Siragy HM, Carey RM. Angiotensin type 2 receptors: potential importance in the regulation of blood pressure. Curr Opin Nephrol Hypertens 2001, 10:99-103
Sleight P. Angiotensin II and trials of cardiovascular outcomes. Am J Cardiol 2002, 89:11-16; discussion 16-17
72
St Lezin E, Liu W, Wang JM, Wang N, Kren V, Krenova D, Musilova A, Zdobinska M, Zidek V, Lau D, Pravenec M. Genetic isolation of a chromosome 1 region affecting blood pressure in the spontaneously hypertensive rat. Hypertension 1997, 30:854-859
Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. Lancet. 2003, 361:1629-1641.
Stirling D, Magness RR, Stone R, Waterman MR, Simpson ER. Angiotensin II inhibits luteinizing hormone-stimulated cholesterol side chain cleavage expression and stimulates basic fibroblast growth factor expression in bovine luteal cells in primary culture. J Biol Chem 1990, 265:5-8
Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T, Martin GR, Black CM, Abraham D. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001, 108:241-250
Stratton R, Rajkumar V, Ponticos M, Nichols B, Shiwen X, Black CM, Abraham DJ, Leask A. Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway. FASEB J 2002, 16:1949-1951
Suh JH, Shigeno ET, Morrow JD, Cox B, Rocha AE, Frei B, Hagen TM. Oxidative stress in the aging rat heart is reversed by dietary supplementation with (R)-()-lipoic acid. FASEB J 2001, 15:700-706
Sumpio BE, Banes AJ, Link WG, Johnson G Jr. Enhanced collagen production by smooth muscle cells during repetitive mechanical stretching. Arch Surg 1988, 10:1233-1236
Sun Y, Zhang JQ, Zhang J, Ramires FJ. Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart. J Mol Cell Cardiol 1998, 30:1559-1569
Suzuma K, Naruse K, Suzuma I, Takahara N, Ueki K, Aiello LP, King GL. Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells. J Biol Chem 2000, 275:40725-40731
Takano H, Komuro I, Zou Y, Kudoh S, Yamazaki T, Yazaki Y. Activation of p70 S6 protein kinase is necessary for angiotensin II-induced hypertrophy in neonatal rat cardiac myocytes. FEBS Lett 1996, 379:255-259
Tamatani T, Kobayashi H, Tezuka K, Sakamoto S, Suzuki K, Nakanishi T, Takigawa M, Miyano T. Establishment of the enzyme-linked immunosorbent assay for connective tissue growth factor (CTGF) and its detection in the sera of biliary atresia. Biochem Biophys Res Commun 1998, 251:748-752
Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, Raymer JM, Romero JC, Wiesner RH, Krom RA, Burnett JC. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994, 69:1182-1193
Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993, 45:205-251
73
Touyz RM, Milne FJ, Seftel HC, Reinach SG. Magnesium, calcium, sodium and potassium status in normotensive and hypertensive Johannesburg residents. S Afr Med J 1987, 72:377-381
Touyz RM, Milne FJ, Reinach SG. Intracellular Mg2+, Ca2+, Na2+ and K+ in platelets and erythrocytes of essential hypertension patients: relation to blood pressure. Clin Exp Hypertens A 1992, 14:1189-1209
Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000, 52:639-672
Touyz RM, Yao G. Inhibitors of Na+/Mg2+ exchange activity attenuate the development of hypertension in angiotensin II-induced hypertensive rats. J Hypertens 2003, 21:337-344
Touyz RM. Role of magnesium in the pathogenesis of hypertension. Mol Aspects Med 2003, 24:107-136
Trippodo NC, Frohlich ED. Similarities of genetic (spontaneous) hypertension. Man and rat. Circ Res 1981, 48:309-319
Tuomilehto J, Jousilahti P, Rastenyte D, Moltchanov V, Tanskanen A, Pietinen P, Nissinen A. Urinary sodium excretion and cardiovascular mortality in Finland: a prospective study. Lancet 2001, 357:848-851
van Wamel AJ, Ruwhof C, van der Valk-Kokshoorn LJ, Schrier PI, van der Laarse A. Stretch-induced paracrine hypertrophic stimuli increase TGF-beta1 expression in cardiomyocytes. Mol Cell Biochem 2002, 236:147-153.
Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D'Agostino RB. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Heart Study. Circulation 2003, 107:1486-1491
Wahab NA, Brinkman H, Mason RM. Uptake and intracellular transport of the connective tissue growth factor: a potential mode of action. Biochem J 2001, 359:89-97
Wahab NA, Yevdokimova N, Weston BS, Roberts T, Li XJ, Brinkman H, Mason RM. Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J 2001, 359:77-87
Wang SN, Lapage J, Hirschberg R. Glomerular ultrafiltration and apical tubular action of IGF-I, TGF-beta, and HGF in nephrotic syndrome. Kidney Int 1999, 56:1247-1251
Weber KT. Cardioreparation in hypertensive heart disease. Hypertension 2001, 38:588-591
Wenger C, Ellenrieder V, Alber B, Lacher U, Menke A, Hameister H, Wilda M, Iwamura T, Beger HG, Adler G, Gress TM. Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene 1999, 18:1073-1080
74
Wikman-Coffelt J, Parmley WW, Mason DT. The cardiac hypertrophy process. Analyses of factors determining pathological vs. physiological development. Circ Res 1979, 45:697-707
Williams B. Angiotensin II and the pathophysiology of cardiovascular remodeling. Am J Cardiol 2001, 87:10-17
Williams R, Van Gaal L, Lucioni C; CODE-2 Advisory Board. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 2002, 45:13-17
Workalemahu G, Foerster M, Kroegel C, Braun RK. Human gamma delta-T lymphocytes express and synthesize connective tissue growth factor: effect of IL-15 and TGF-beta 1 and comparison with alpha beta-T lymphocytes. J Immunol 2003, 170:153-157
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000, 342:145-153.
Zafari AM, Ushio-Fukai M, Minieri CA, Akers M, Lassegue B, Griendling KK. Arachidonic acid metabolites mediate angiotensin II-induced NADH/NADPH oxidase activity and hypertrophy in vascular smooth muscle cells. Antioxid Redox Signal 1999, 1:167-179
Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999, 107:421-430
Zou Y, Takano H, Akazawa H, Nagai T, Mizukami M, Komuro I. Molecular and cellular mechanisms of mechanical stress-induced cardiac hypertrophy. Endocr J 2002, 49:1-13
75
ORIGINAL PUBLICATIONS